

10/27/00
JC850 U.S. PTO

10/30/00
A

CHOATE, HALL & STEWART

A PARTNERSHIP INCLUDING PROFESSIONAL CORPORATIONS

EXCHANGE PLACE

53 STATE STREET

BOSTON, MASSACHUSETTS 02109-2891

TELEPHONE (617) 248-5000

FACSIMILE (617) 248-4000

Box PATENT APPLICATION
ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Express Mail No.: EE441114555US
Attorney Docket No.: 2001796-0006
Date Filed: October 27, 2000

JC853 U.S. PTO
10/27/00

10/27/00

UTILITY PATENT APPLICATION TRANSMITTAL

(FOR NEW NONPROVISIONAL APPLICATIONS UNDER 37 C.F.R. § 1.53(B))

Dear Sir:

Please find enclosed a patent application and papers as follows for:

Inventor(s):

Given Name (first and middle) Family Name or Surname Residence (City and State or Foreign Country)

A. John	Bramley	Hinesburg, VT
Karen I.	Plaut	Westford, VT
David	Kerr	Charlotte, VT

Title of the Invention: TREATMENT OF STAPHYLOCOCCUS INFECTIONS

A) APPLICATION ELEMENTS:

1) **Fee Transmittal Form** (original and duplicate submitted for fee processing)

2) **Applicant Claims Small Entity Status** (see 37 CFR 1.27)

a) **Statement Verifying Small Entity Status (optional)**

EXPRESS MAIL NO. EE441114555US
DATE FILED: OCTOBER 27, 2000

PAGE 1 OF 4

3183928_1.DOC

- 3) **Specification** TOTAL PAGES: 41
- Descriptive Title of the Invention
 - Cross References to Related Applications
 - Background of the Invention
 - Summary of the Invention
 - Description of the Drawing (if filed)
 - Description of the Sequence Listing
 - Definitions
 - Detailed Description of Certain Preferred Embodiments of the Invention
 - Examples
 - Other Embodiments
 - Claim(s)
 - Abstract of the Invention

4) **Drawing(s)** (35 U.S.C. § 113) TOTAL SHEETS: 29

- a) Formal Drawings (if checked)

5) **Oath or Declaration** TOTAL PAGES: 9

- a) Newly Executed (original or copy)
- b) Copy from a prior application (37 C.F.R. § 1.63(d))-for continuation/divisional application
 - i) DELETION OF INVENTOR(S): Signed Statement deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).
- c) Unexecuted

6) **Application Data Sheet**. See 37 CFR §1.76.

7) **CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)**

8) **Nucleotide and/or Amino Acid Sequence Submission** (if applicable, all are necessary)

- a) Computer Readable Form (CRF)
- b) Specification Sequence Listing on:
 - i) CD-ROM or CR-R (2 copies); or
 - ii) Paper

- c) Statement verifying identity of above copies
- d) Amendment introducing Sequence Listing into specification.

B) ACCOMPANYING APPLICATION PARTS:

- 9) **Assignment Papers** (copies of assignments in parent application, included with 37 CFR §3.73(b) statement)
- 10) **37 C.F.R. § 3.73(b) Statement** (copy from parent application)
- 11) **Appointment of Attorney** (copy from parent application)
- 12) **English Translation Document** (if applicable)
- 13) **Information Disclosure Statement (IDS)/PTO-1449**
- 14) **Copies of IDS Citations**
- 15) **Preliminary Amendment**
- 16) **Return Receipt Postcard (MPEP 503)** (specifically itemized)
- 17) **Certified Copy of Priority Document(s)** (if foreign priority is claimed)
- 18) **OTHER:** (if applicable, specified below)

C) FOR CONTINUING APPLICATIONS: (the appropriate box is checked, and certain information is provided below)

CONTINUATION DIVISIONAL CONTINUATION-IN-PART (CIP)

OF PRIOR APPLICATION NO: 09/337,079
FILED: JUNE 21, 1999
EXAMINER: WOITACH
GROUP/ART UNIT: 1633

FOR CONTINUATION OR DIVISIONAL APPLICATIONS ONLY: The entire disclosure of the prior application, from which an oath or declaration is supplied as detailed above,

EXPRESS MAIL NO. EE441114555US
DATE FILED: OCTOBER 27, 2000

is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

D) METHOD OF PAYMENT OF FILING FEES FOR THIS APPLICATION:

- Applicant claims small entity status 37 CFR §1.27
- A check is enclosed to cover the filing fees as determined on the fee transmittal enclosed herewith
- The commissioner is hereby authorized to charge filing fees or credit any overpayment to deposit account number 03-1721.

Total filing fee amount \$ 710.00

E) CORRESPONDENCE ADDRESS:

Customer Bar Code Label: _____

Correspondence Address:

Brenda Herschbach Jarrell
Choate, Hall & Stewart
53 State Street
Exchange Place
Boston, MA 02109
email: BHJ@choate.com
phone: (617) 248-5000
fax: (617) 248-4000

Respectfully Submitted,



Brenda Herschbach Jarrell, Ph.D.
Reg. No.: 39,223

CHOATE, HALL & STEWART
53 State Street
Exchange Place
Boston, MA 02109
Phone: (617) 248-5000
Fax: (617) 248-4000
Date: October 27, 2000

EXPRESS MAIL NO. EE441114555US
DATE FILED: OCTOBER 27, 2000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL

for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$)


Complete if Known

Application Number	
Filing Date	October 27, 2000
First Named Inventor	Bramley, et al.
Examiner Name	
Group Art Unit	
Attorney Docket No.	2001796-0006

METHOD OF PAYMENT				FEE CALCULATION (continued)																																																																																																																																																																																																									
<p>1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:</p> <p>Deposit Account Number 03-1721</p> <p>Deposit Account Name Choate, Hall & Stewart</p> <p><input type="checkbox"/> Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17</p> <p><input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27</p>				<p>3. ADDITIONAL FEES</p> <table border="1"> <thead> <tr> <th>Large Entity</th> <th>Small Entity</th> <th>Fee Code (\$)</th> <th>Fee Code (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr><td>105</td><td>130</td><td>205</td><td>65</td><td>Surcharge - late filing fee or oath</td><td></td></tr> <tr><td>127</td><td>50</td><td>227</td><td>25</td><td>Surcharge - late provisional filing fee or cover sheet</td><td></td></tr> <tr><td>139</td><td>130</td><td>139</td><td>130</td><td>Non-English specification</td><td></td></tr> <tr><td>147</td><td>2,520</td><td>147</td><td>2,520</td><td>For filing a request for ex parte reexamination</td><td></td></tr> <tr><td>112</td><td>920*</td><td>112</td><td>920*</td><td>Requesting publication of SIR prior to Examiner action</td><td></td></tr> <tr><td>113</td><td>1,840*</td><td>113</td><td>1,840*</td><td>Requesting publication of SIR after Examiner action</td><td></td></tr> <tr><td>115</td><td>110</td><td>215</td><td>55</td><td>Extension for reply within first month</td><td></td></tr> <tr><td>116</td><td>390</td><td>216</td><td>195</td><td>Extension for reply within second month</td><td></td></tr> <tr><td>117</td><td>890</td><td>217</td><td>445</td><td>Extension for reply within third month</td><td></td></tr> <tr><td>118</td><td>1,390</td><td>218</td><td>695</td><td>Extension for reply within fourth month</td><td></td></tr> <tr><td>128</td><td>1,890</td><td>228</td><td>945</td><td>Extension for reply within fifth month</td><td></td></tr> <tr><td>119</td><td>310</td><td>219</td><td>155</td><td>Notice of Appeal</td><td></td></tr> <tr><td>120</td><td>310</td><td>220</td><td>155</td><td>Filing a brief in support of an appeal</td><td></td></tr> <tr><td>121</td><td>270</td><td>221</td><td>135</td><td>Request for oral hearing</td><td></td></tr> <tr><td>138</td><td>1,510</td><td>138</td><td>1,510</td><td>Petition to institute a public use proceeding</td><td></td></tr> <tr><td>140</td><td>110</td><td>240</td><td>55</td><td>Petition to revive - unavoidable</td><td></td></tr> <tr><td>141</td><td>1,240</td><td>241</td><td>620</td><td>Petition to revive - unintentional</td><td></td></tr> <tr><td>142</td><td>1,240</td><td>242</td><td>620</td><td>Utility issue fee (or reissue)</td><td></td></tr> <tr><td>143</td><td>440</td><td>243</td><td>220</td><td>Design issue fee</td><td></td></tr> <tr><td>144</td><td>600</td><td>244</td><td>300</td><td>Plant issue fee</td><td></td></tr> <tr><td>122</td><td>130</td><td>122</td><td>130</td><td>Petitions to the Commissioner</td><td></td></tr> <tr><td>123</td><td>50</td><td>123</td><td>50</td><td>Petitions related to provisional applications</td><td></td></tr> <tr><td>126</td><td>240</td><td>126</td><td>240</td><td>Submission of Information Disclosure Stmt</td><td></td></tr> <tr><td>581</td><td>40</td><td>581</td><td>40</td><td>Recording each patent assignment per property (times number of properties)</td><td></td></tr> <tr><td>146</td><td>710</td><td>246</td><td>355</td><td>Filing a submission after final rejection (37 CFR § 1.129(a))</td><td></td></tr> <tr><td>149</td><td>710</td><td>249</td><td>355</td><td>For each additional invention to be examined (37 CFR § 1.129(b))</td><td></td></tr> <tr><td>179</td><td>710</td><td>279</td><td>355</td><td>Request for Continued Examination (RCE)</td><td></td></tr> <tr><td>169</td><td>900</td><td>169</td><td>900</td><td>Request for expedited examination of a design application</td><td></td></tr> <tr><td colspan="6">Other fee (specify) _____</td></tr> <tr> <td colspan="4">*or number previously paid, if greater; For Reissues, see above</td> <td>SUBTOTAL (1) (\$)</td> <td>710.00</td> </tr> <tr> <td colspan="4"></td> <td>SUBTOTAL (2) (\$)</td> <td>0.00</td> </tr> <tr> <td colspan="4"></td> <td>Reduced by Basic Filing Fee Paid</td> <td>SUBTOTAL (3) (\$)</td> </tr> </tbody> </table>				Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid	105	130	205	65	Surcharge - late filing fee or oath		127	50	227	25	Surcharge - late provisional filing fee or cover sheet		139	130	139	130	Non-English specification		147	2,520	147	2,520	For filing a request for ex parte reexamination		112	920*	112	920*	Requesting publication of SIR prior to Examiner action		113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		115	110	215	55	Extension for reply within first month		116	390	216	195	Extension for reply within second month		117	890	217	445	Extension for reply within third month		118	1,390	218	695	Extension for reply within fourth month		128	1,890	228	945	Extension for reply within fifth month		119	310	219	155	Notice of Appeal		120	310	220	155	Filing a brief in support of an appeal		121	270	221	135	Request for oral hearing		138	1,510	138	1,510	Petition to institute a public use proceeding		140	110	240	55	Petition to revive - unavoidable		141	1,240	241	620	Petition to revive - unintentional		142	1,240	242	620	Utility issue fee (or reissue)		143	440	243	220	Design issue fee		144	600	244	300	Plant issue fee		122	130	122	130	Petitions to the Commissioner		123	50	123	50	Petitions related to provisional applications		126	240	126	240	Submission of Information Disclosure Stmt		581	40	581	40	Recording each patent assignment per property (times number of properties)		146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))		149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))		179	710	279	355	Request for Continued Examination (RCE)		169	900	169	900	Request for expedited examination of a design application		Other fee (specify) _____						*or number previously paid, if greater; For Reissues, see above				SUBTOTAL (1) (\$)	710.00					SUBTOTAL (2) (\$)	0.00					Reduced by Basic Filing Fee Paid	SUBTOTAL (3) (\$)
Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid																																																																																																																																																																																																								
105	130	205	65	Surcharge - late filing fee or oath																																																																																																																																																																																																									
127	50	227	25	Surcharge - late provisional filing fee or cover sheet																																																																																																																																																																																																									
139	130	139	130	Non-English specification																																																																																																																																																																																																									
147	2,520	147	2,520	For filing a request for ex parte reexamination																																																																																																																																																																																																									
112	920*	112	920*	Requesting publication of SIR prior to Examiner action																																																																																																																																																																																																									
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action																																																																																																																																																																																																									
115	110	215	55	Extension for reply within first month																																																																																																																																																																																																									
116	390	216	195	Extension for reply within second month																																																																																																																																																																																																									
117	890	217	445	Extension for reply within third month																																																																																																																																																																																																									
118	1,390	218	695	Extension for reply within fourth month																																																																																																																																																																																																									
128	1,890	228	945	Extension for reply within fifth month																																																																																																																																																																																																									
119	310	219	155	Notice of Appeal																																																																																																																																																																																																									
120	310	220	155	Filing a brief in support of an appeal																																																																																																																																																																																																									
121	270	221	135	Request for oral hearing																																																																																																																																																																																																									
138	1,510	138	1,510	Petition to institute a public use proceeding																																																																																																																																																																																																									
140	110	240	55	Petition to revive - unavoidable																																																																																																																																																																																																									
141	1,240	241	620	Petition to revive - unintentional																																																																																																																																																																																																									
142	1,240	242	620	Utility issue fee (or reissue)																																																																																																																																																																																																									
143	440	243	220	Design issue fee																																																																																																																																																																																																									
144	600	244	300	Plant issue fee																																																																																																																																																																																																									
122	130	122	130	Petitions to the Commissioner																																																																																																																																																																																																									
123	50	123	50	Petitions related to provisional applications																																																																																																																																																																																																									
126	240	126	240	Submission of Information Disclosure Stmt																																																																																																																																																																																																									
581	40	581	40	Recording each patent assignment per property (times number of properties)																																																																																																																																																																																																									
146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))																																																																																																																																																																																																									
149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))																																																																																																																																																																																																									
179	710	279	355	Request for Continued Examination (RCE)																																																																																																																																																																																																									
169	900	169	900	Request for expedited examination of a design application																																																																																																																																																																																																									
Other fee (specify) _____																																																																																																																																																																																																													
*or number previously paid, if greater; For Reissues, see above				SUBTOTAL (1) (\$)	710.00																																																																																																																																																																																																								
				SUBTOTAL (2) (\$)	0.00																																																																																																																																																																																																								
				Reduced by Basic Filing Fee Paid	SUBTOTAL (3) (\$)																																																																																																																																																																																																								

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Brenda Herschbach Jarrell	Registration No. (Attorney/Agent)	39, 223	Telephone	617-248-5175
Signature			Date	10/27/00	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

TREATMENT OF STAPHYLOCOCCUS INFECTIONS

Related Applications

The present application is a Divisional of co-pending application serial number

5 09/337,079, filed June 21, 1999, the entire contents of which are incorporated herein by reference. Furthermore, this parent application (09/337,079) claimed the benefit of priority of a co-pending provisional application serial number 60/090,175, filed June 22, 1998, the entire contents of which are hereby incorporated by reference.

10

Background of the Invention

Bovine staphylococcal mastitis is a frequent problem for the dairy industry, and leads to estimated annual economic losses of \$184 per cow per year. This corresponds to a U.S. total of \$1.7 billion per year for milk producers and milk processors. These losses arise from reduced milk yield, reduced compositional quality, lower product quality and increased veterinary cost.

15

Mastitis is transmitted from cow to cow at milking time. *Staphylococcus aureus* (*S. aureus*) is a major pathogen that infects both humans and animals, and that accounts for 15 to 30% of intramammary infection cows. *Staphylococcus* infections are often characterized by their persistence and their deleterious effects on milk production and quality. Current therapies and preventative treatments for staphylococcal mastitis rely heavily on sterilization techniques, selective culling of animals with chronic recurring mastitis, and the use of β -lactam antibiotics such as cepharin and penicillin derivatives (Bramley, et al., *J. Dairy Res.*, Craven, et al., *J. Dairy Res.*, 51:513-523, 1984). Also, numerous attempts have been made to develop vaccines, but none have stood the test of time (Derbyshire and Smith, *Res. Vet. Sci.* 109:559, 1969; Nelson L. et al., *Flem. Vet. J.*, 62 Suppl., 1:111; Rainard et al., *Flem. Vet. J.* 62 Suppl., 1:141; Watson et al., *Proc. Int. Symp. Bovine Mastitis Indianapolis*, 73). Although sterilization techniques and the use of antibiotics have had a positive impact on dairy animal health

Express Mail No. EE441114555US
3183367_1.DOC

and milk production, the prognosis for the elimination of *S. aureus* infection is poor, with often less than a 15% cure rate. This problem may be attributable to incomplete penetration of the antibiotics and/or sequestration of the bacteria within the host cells, leading to a relapse of the infection once treatment has ended (Craven and Anderson, 5 *supra*). The widespread use of antibiotics in dairy animals is also of great concern to the consumer. One problem is accidental exposure of the consumer to the antibiotic drug that can induce a strong immune response and result in anaphylaxis. A second concern is that the overuse of antibiotics selects for microorganisms that are resistant to the antibiotic. Many *S. aureus* strains have already acquired resistance to commonly 10 used antibiotics such as ampicillin and penicillin. Such prevalent problems have made it necessary to discard milk for period up to 96 hours after antibiotic treatment of an animal, resulting in an enormous waste of milk product and cost to milk producers.

15 There is a need for the development of an improved approach to treating mastitis infections.

15

Summary of the Invention

The present invention provides an improved approach for the treatment of microbial infections in mammals. In particular, the invention provides methods and reagents for expressing in mammalian cells microbial proteins that have anti-microbial, particularly anti-staphylococcal, activity. The invention provides both altered genes, in which the naturally-occurring microbial sequences have been engineered to allow expression of active protein in desired mammalian cells or tissues, and methods of introducing such altered genes into desired mammalian cells and/or tissues. In certain preferred embodiments, an altered gene is modified in such a manner that the protein it 20 encodes is not only produced in mammalian cells, but is secreted from those cells, so that a local concentration of anti-staphylococcal protein is created outside of the cells. Most preferably, such cells either are, or are in the vicinity of, cells that are targeted by 25 infectious microbes *S. aureus* for attachment and penetration. In alternative preferred

embodiments, an altered gene is prepared so that the anti-microbial protein is expressed within cells that are sensitive to intracellular infection.

The teachings of the present invention are particularly applicable to treatment of staphylococcal mastitis infections in ruminants, such as cows, goats, and sheep, and most particularly in cows. In certain preferred embodiments of the invention, the altered gene is delivered to mammary tissue in a form and through a mechanism that allows transient transfection of certain cells, preferably localized within the lining of the teat. In alternative preferred embodiments, the altered gene is delivered through the production of a transgenic animal. Any of a variety of anti-microbial agents may be employed according to the present invention, but one particularly preferred agent is lysostaphin. In preferred embodiments the natural lysostaphin gene is altered to contain one or more of a mammalian promoter, transcriptional regulatory sequence, transcriptional termination signal and/or polyA site, splicing sequences, and translation initiation sequences. Preferred altered genes also include sequences that mediate lysostaphin export from the mammalian cells in which the protein is expressed. Particularly preferred altered genes contain sequence modifications that disrupt one or more post-translational processing events that would otherwise occur upon expression of the lysostaphin protein in the mammalian cells.

20 Description of the Drawing

Figure 1 is a schematic representation of the preprolysostaphin polypeptide.

Figure 2 is a representation of modifications of the lysostaphin gene for eukaryotic expression.

Figure 3 is an experiment demonstrating lysis of *S. aureus* by bioactive lysostaphin produced by COS-7 cells transfected with pCMV-Lys. Conditioned media or cell extracts were lyophilized and resuspended with the original volume (1X), 0.5 volume (2X), or 0.25 volume (4X) of H₂O. Lysostaphin standards were prepared in media. Samples or standards (15 µl) were then applied to an LB agar plate freshly

streaked with *S. aureus* and incubated 16 hr, 37 °C. Top row, lysostaphin standards at concentrations of 10, 33, 100, and 333 µg/ml; middle row, blank, 1X, 2X, 4X cell extract; bottom row, blank, 1X, 2X, 4X conditioned media.

Figure 4 is a Western blot analysis of conditioned media samples treated with or

5 without N-glycosidase-F. Molecular size standards are shown on the left. Samples in lanes 1,2, and 3 were untreated, and contain 20 µl of media from COS-7 cells
transfected with: pCMV-hGH control, spiked with 1 µg/ml lysostaphin (lane 1), pCMV-
hGH control (lane 2), pCMV-hGH-Lys (lane 3). Samples in lanes 4 and 6 were
incubated with deglycosylation buffers, no enzyme, for 16 hr, 37 °C. Sample in lane 5
10 was incubated with deglycosylation buffers, and enzyme, for 16 hr, 37 °C. Lanes
contain 20 ul of media from COS-7 cells transfected with; p CMV-hGH (lanes 4), pCMV-
hGH-Lys (lanes 5, 6). Figure 5 is a bacterial plate assay for detection of lysis of *S.*
aureus (M60) by media or cell extracts from transfected COS-7 cells. Media and cell
extracts were obtained 48 hr post transfection with (1) pCMV-Lys, (2) pCMV-hGH-Lys,
15 (3) pCMV-hGH-Lys-ΔGly1-ΔGly2, (4) pCMV-hGH genomic as a control. Conditioned
media or cell extracts were lyophilized and resuspended with one third the original
volume of H₂O. Top row : Lysostaphin standards at concentrations of 11, 33, 100 or
300 ng/ml in media. Second row: Conditioned media, Third row: cell extracts. Bottom
row: Lysostaphin standards that were diluted 1:3 in media, lyophilized, and
20 resuspended with one third the original volume of H₂O.

Figure 6 represents western blot analysis of lysostaphin expressed in transfected
COS-7 cells. Proteins were separated on a 12% polyacrylamide-SDS gel, transferred
to nitrocellulose membranes and probed with a rabbit anti-lysostaphin polyclonal
antibody. Bound antibodies were detected with an alkaline phosphatase-linked second
25 antibody and BCIP/NBT substrate. Molecular size standards are shown on the left.
Lanes contain 50 µl cell extract (CE), or media (M), respectively, from cells transfected
with: pCMB-hGH as control (lanes 1,2), pCMV-hGH-Lys (lanes 3,4), pCMV-hGH-Lys-
ΔGly2 (lanes 5,6), pCMV-hGH with standard lysostaphin protein added to 1 µg /ml

(lanes 7,8), Ad-preprolysostaphin (lanes 10,11). Lane 9 (*) contained culture media and Ad-preprolysostaphin as used for infection.

Figure 7 shows tissue fragments, tissue section and cultured cells, exposed to the X-gal reagent for visualization of β -galactosidase activity (panel A-E). (A) Teat tissue, (B) adjacent mammary tissue, (C) sections of teat tissue (40x), (D) primary culture of mammary tissue from one goat mammary gland transfected with LacZ-containing adenovirus (Av1Lac4) by intramammary infusion. The contralateral gland was infused with vehicle and blue staining was not observed (lower tissue pieces panel A and B). (E) Bovine mammary epithelial cell line (BME-UV) following transfection with AvLacZ4. (F) Green fluorescent protein in COS-7 cells transfected with the GFP gene.

Figure 8 depicts lysis of *S. aureus* by bioactive lysostaphin produced by 293 cells infected with Ad-hGH-Lys- Δ GLY1- Δ GLY2. Lysostaphin standards were prepared in media. The concentrations were 3 ng/ μ l, 30 ng/ μ l and 100 ng/ μ l. Samples (60 μ l) or standards (15 μ l) were added to a LB agar plate freshly streaked with *S. aureus*.

Results were evaluated following a 12 hour incubation at 37°. Top row, from left to right, lysostaphin standards at concentrations of 3, 100, 30 ng/ μ l; middle row, from left to right: cell culture media of 293 cells infected by Ad-hGH-Lys- Δ GLY1- Δ GLY2 isolates #4 and #6, and by 293 cells infected with parent virus Addl 327. bottom row, from left to right: fresh cell culture media, cell culture media of 293 cells infected by Addl 327, and cell culture media of uninfected 293 cells.

Figure 9 shows a Western blot of lysostaphin in milk from transgenic mice containing the BLG-Lys- Δ GLY1- Δ GLY2 construct. Lane 1 contains 10 μ l of lysostaphin standard (Sigmas 1 μ g/ μ l) in PBS - 1% BSA. Lanes 2-4 contain milk samples from three different transgenic mice (10 μ l milk diluted 1:10 in PBS - 1% BSA)

Lysostaphin was not detected in non-transgenic mouse milk.

Figure 10 shows a bacterial plate assay for lysostaphin bioactivity in mouse milk. Milk samples or lysostaphin standards (15 μ l) were spotted onto a freshly plated lawn

of *S. aureus*, and lytic zones were observed after overnight incubation. Top row, left to right: bacterially derived lysostaphin (Sigma, 500, 250, 125, 62 ng/ml in PBS-1% BSA Middle row, left to right: skim milk from a BLG-Lys- transgenic mouse (#16755) diluted 1:200, 1:400, 1:800 or 1:1600 in PBS - 1% BSA. Bottom row, left to right: skim milk 5 from a non-transgenic mouse diluted 1:200, 1:400, 1:800 1:1600 in PBS - 1% BSA.

Figure 11 depicts the entire DNA sequence of the lysostaphin gene cloned by Recsei et al, *Proc. Natl. Acad. Sci. U.S.A.*, 84:1127-1131, 1987 (A), and the DNA sequence encoding the mature lysostaphin protein (Recsei et al., *supra*) (B).

Figure 12 depicts the preprolysostaphin amino acid sequence encoded by the 10 lysostaphin gene cloned by Recsei et al., *supra*.

Figure 13 depicts the DNA coding sequence of the mature lysostaphin protein of the present invention containing 12 amino acid substitutions as compared to the Recsei et al. (*supra*) sequence. The modified sequence encodes a 246 amino acid protein in which all but 2 amino acids are identical to the protein encoded by the Recsei 15 et al. (*supra*) sequence.

Figure 14 depicts the DNA sequence of the β-lytic protease gene (Li et al., *J. Bacteriol.*, 172:6506-6511, 1990) (A), and the β-lytic protease amino acid sequence encoded by the β-lytic protease gene (B).

Figure 15 depicts the lysostaphin DNA sequence cloned by Heinrich et al., (*Mol. Gen. Genet.*, 209:563-569, 1987) (A), and the amino acid sequence encoded by that gene (B).

Figure 16 depicts the DNA sequence of the lysostaphin gene cloned by Thumm and Gotz et al. (*Mol. Microbiol.*, 23:1251-1265, 1997). The sequence presented encodes three bacterial genes. Lysostaphin is encoded by nucleotides 725-2018 of the 25 DNA sequence.

Figure 17 depicts the amino acid sequence of the lysostaphin gene cloned by (Thumm and Gotz et al., *supra*).

Description of the Sequence Listing

SEQ ID NO:1 is the sequence of the naturally-occurring lysostaphin gene of *S. simulans* (Recsei et al, *supra*) (Figure 11).

SEQ ID NO:2 is the sequence of the naturally-occurring lysostaphin protein. The
5 sequence presented is of the preproprotein (Figure 12).

SEQ ID NO:3 is the sequence of an inventive altered lysostaphin gene (Figure
13).

SEQ ID NO:4 is the β -lytic protease gene from *Achromobacter lyticus* (Figure
14).

10 SEQ ID NO:5 is a second sequence of a naturally-occurring lysostaphin protein
(Heinrich et al., *Mol. Gen. Genet.*, 209:563-569, 1987) (Figure 15).

SEQ ID NO:6 is a third sequence of the naturally-occurring lysostaphin protein
(Thumm and Gotz et al., *Mol. Microbiol.*, 23:1251-1265, 1997) (Figures 16 and 17).

Definitions

15 "Altered gene": An "altered" gene, as that term is used herein, is identical to a naturally-occurring gene except that the nucleotide sequence of the altered gene has been modified with respect to that of the naturally-occurring gene through the addition, deletion, substitution, or inversion, of one or more nucleotide residues. Preferred
20 altered genes are those in which the coding sequence of a microbial anti-staphylococcal agent is operatively linked with mammalian expression sequences. Particularly preferred altered genes are those in which at least a portion of the microbial sequence (sufficient to encode a protein with anti-staphylococcal activity) is linked to sequences that direct the secretion of the protein from mammalian cells. Such
25 preferred altered genes may also include sequence modifications that remove (or add) sites for post-transcriptional modifications that would otherwise occur in the mammalian cells. As will be clear to those of ordinary skill in the art, in the context of "altered gene", a "gene" includes expression signals as well as coding sequence.

“Gene”: Generally speaking, a “gene”, as used herein, is a single transcription unit. However, as will be clear from context and is understood in the art, the term can be used in more than one way. The “gene” for a particular protein always includes the sequence that actually encode the protein. A “gene” may also include regulatory sequences such as sites recognized by transcriptional regulators, or responsible for transcriptional termination. A “gene” may also include intronic sequences and/or splicing signals.

5 “Microbial host”: The term “microbial host” is any self-replicating host of microscopic size that encodes within its nucleic acid genome, an anti-microbial agent.
10 As used herein, “microbial host” can also refer to a plants and fungi that encode within their nucleic acid genome an antimicrobial agent useful in the present invention.

15 “Naturally-occurring”: The term “naturally-occurring” is sometimes used herein to describe microbial genes encoding agents with anti-staphylococcal activity and is intended to refer to the form of the gene (i.e., the gene sequence) that is present in nature, in the microbial host in which the gene is found. Any self-replicating entity that contains nucleic acid and is found in nature can be a “microbial host” for the purposes of this definition. Moreover, although it is not generally so used in common parlance, the term “microbial host”, as used herein, may refer to a plant host.

20 “Operatively linked”: The term “operatively linked” is used herein to refer to nucleic acid sequences that are associated with one another in such a way that they are operative with respect to one another. For example, a promoter is operatively linked to a gene coding sequence when it is associated with that sequence in a manner that allows it to direct transcription of that sequence. Typically, operative linkage involves covalent attachment via a 3'-5' phosphodiester bond. Those of ordinary skill in
25 the art will appreciate that the precise nature of the linkage may vary depending on the nature of the sequences being associated. For example, whereas a promoter is typically required to be 5' (upstream) to gene coding sequences to be operative, other transcriptional regulatory sequences (e.g., enhances) can very often exert effects from

upstream, downstream, or within coding sequences, frequently regardless of orientation.

“Recombinant”: The term “recombinant”, as used herein, refers to a nucleic acid or protein that is produced using the established techniques of recombinant DNA technology (i.e., digestion with restriction endonuclease, ligation, site-specific DNA mutation, polymerase chain reaction, etc.). A recombinant protein is one that is produced from a gene that was made thereof, or from replicative progeny thereof.

“Regulatory sequence”: A regulatory sequence is a region of DNA that, when altered or deleted, has an effect on the expression level of the gene with which it is operationally linked. Typically, regulatory sequences are regions of DNA that are recognized (i.e., bound by) protein factors that participate in the regulation of gene expression.

Detailed Description of Certain Preferred Embodiments

15 Altered Anti-staphylococcal genes

As mentioned above, the present invention provides altered versions of microbial genes that encode agents with anti-microbial activity, the versions having been modified so that they direct expression of active protein in mammalian tissues or cells.

Those of ordinary skill in the art will appreciate that a significant number of microbial proteins, naturally found in any number of microbial hosts, are known to have anti-microbial activity. In principle, the gene encoding any such protein could be altered in accordance with the present invention. Preferred genes include those encoding anti-staphylococcal activity, for example, β -lytic protease, lysostaphin, -lytic protease, lyt-M, at1ALE-1, zooA. Other preferred anti-microbial peptides or proteins whose genes could be utilized include lysozyme, nisin, muramidases, glucoasminidases, and colicins. (see, for example Shockman and Barrett, *Proc. Natl. Acad. Sci. U. S.A.*, 51:414-421, 1964; Yamada et al., *J. Bacteriol.*, 178:1565-1571, 1996). Particularly preferred are genes encoding bacteriocins, which are peptide antibiotics that are produced by

bacteria and are effective against even closely related species but do not have significant deleterious effects on the species that produces them or on eukaryotic cells. One particularly preferred bacteriocin gene is the lysostaphin gene.

ALTERED LYSOSTAPHIN GENES

5 Lysostaphin is naturally produced by *Staphylococcus simulans*. Lysostaphin kills closely related staphylococcal species, but does not harm other bacterial species or eukaryotic cells. Lysostaphin has endopeptidase activity and kills cells by hydrolyzing the pentapeptide links of staphylococcal cell walls, causing the cells to lyse (Schindler and Schuhardt, *Proc. Natl. Acad. Sci. U.S.A.*, 51:414-421, 1964). If injected directly
10 into the mammary gland of mice or dairy cattle, recombinant lysostaphin is protective against staphylococcal infection (Bramley and Foster, *Res. Vet. Sci.*, 49:120-121, 1990; Oldham and Daley, *J. Dairy. Sci.*, 74:4175-4182, 1991). The minimum inhibitory concentrations of recombinant lysostaphin against *S. aureus* are less than 100 ng per ml in culture media and less than 2 µg per ml in milk, (Bramley and Foster, *Res. Vet. Sci.*, 49:120-121, 1990; Oldham and Daley, *J. Dairy Sci.*, 74:4175-4182, 1991). This low concentration requirement makes lysostaphin an attractive candidate for the prevention and treatment of mastitis, because one requirement of the present invention is that the protein be expressed and secreted at sufficient concentrations *in vivo* to kill *S. aureus*.

20 The gene encoding lysostaphin is naturally found on a large plasmid in *S. simulans*, and encodes a preproenzyme that is processed extracellularly to a mature form, which is active (Figure 1). Several allelic variations of this gene have been identified that are apparently found in nature. (Heinrich et al., *supra*, (SEQ ID NO: 5) (Figure 13); Recsei et al, *supra*, (SEQ ID NO: 1) (Figure 11); Thumm and Gotz et al.,
25 *supra*, (SEQ ID NO: 6) (Figure 14); U.S. Patent No. 4,931,390). The sequence of mature lysostaphin identified by Heinrich, (et al., *supra*) differs from the sequence identified by Recsei, (et al. *supra*) by one amino acid, whereas prolysostaphin has multiple differences. Furthermore, the prolysostaphin sequence identified by

Thumm and Gotz et al., (*supra*) differs from the preprolysostaphin sequence identified by both Recsei et al ., (*supra*) and Heinrich et al., (*supra*). According to Thumm and Gotz et al., (*supra*), preprolysostaphin is 493 amino acids having a signal peptide of 36 amino acids, a propeptide of 211 amino acids and a mature lysostaphin protein of 246

5 amino acids.

In the present application the term "mature form" refers to a lysostaphin protein which has had the propeptide cleaved off. It should be noted, however, that "active forms" of lysostaphin are not limited to the mature form; other unprocessed forms of lysostaphin also have activity. In particular, preprolysostaphin and prolysostaphin.

10 Prolysostaphin is bioactive, but mature lysostaphin is 4.5 times more bioactive than prolysostaphin (Thumm and Gotz et al., *supra*). Variations of lysostaphin that can be modified to be expressed in an active form in mammalian cells fall within the scope of the presently claimed invention.

In order to prepare an altered lysostaphin gene according to the present invention, the naturally-occurring lysostaphin gene sequence must be modified to allow for expression of active lysostaphin protein in mammalian cells. As will be appreciated by those of ordinary skill in the art, expression of bacterial proteins in mammalian cells is often not trivial. Typically, the bacterial coding sequence must be operatively linked to a mammalian, or at least a eukaryotic, promoter and a eukaryotic translation initiation sequence. Although it is often not required that every nucleotide of coding sequence be preserved, or that the coding sequence initiate and terminate at precisely the same points as it does in its natural host system (fusion proteins and modest deletions are usually tolerated), it is essential that the coding sequence to be employed be operatively linked to expression signals that are effective in the cells into which the

20 altered gene is to be introduced.

A large number of different eukaryotic, and particularly mammalian, expression signals are known in the art and include promoters, transcriptional regulatory sequences (often provided in conjunction with the promoter with which they are

naturally associated, or with a promoter with which they have previously been experimentally associated), transcriptional termination signals, splicing signals, translation initiation signals, post-transnational processing signals, and secretory signals (see, for example, *Current Protocols* 16.0 - 16.21.9). Those of ordinary skill in the art will appreciate that not every one of such signals must be employed in an altered gene of the present invention. It is generally preferred to include eukaryotic (preferably mammalian) transcription and translation initiation signals; other sequences may be employed as necessary or desirable. Various other modifications may also be made.

Promoters that may be employed include constitutive promoters, inducible promoters, universal promoters (*i.e.*, active in substantially all cell types), and/or tissue specific promoters. Those of ordinary skill in the art will appreciate that the precise application of the inventive altered gene will determine which category of promoter is more desirable. For example, if expression is desirably limited to a particular tissue, a tissue-specific promoter is employed; if expression is desirably limited to times when certain environmental conditions are present, an inducible promoter responsive to those environmental conditions is employed. Particular promoters are also selected on the basis of their ability to direct higher or lower levels of transcription.

As mentioned above and discussed more fully below, in certain preferred embodiments of the present invention, an altered lysostaphin gene is to be expressed in mammary tissue. If the altered gene is to be introduced only into mammary cells, a tissue-specific promoter is not required. Preferred promoters for use in such circumstances include, but are not limited to, Cytomegalovirus, (CMV), Rous Sarcoma Virus (RSV) and human elongation factor 1 (EF-1) λ subunit. Particularly preferred is CMV. Of course, a tissue-specific promoter may nonetheless be employed. Known mammary-specific promoters include, for example, β -lactoglobulin, λ -lactalbumen, caseins and whey acidic protein. Particularly preferred is the β -lactoglobulin promoter.

The Kozak sequence is well established to be the eukaryotic translation initiation sequence and is the preferred sequence to be introduced into altered genes of the present invention.

Williamson and colleagues have previously reported that operative linkage of the entire lysostaphin gene to the human cytomegalovirus promoter and the Kozak initiation sequence is sufficient to direct expression of lysostaphin in COS-7 cells, but active enzyme was not secreted from the cells (Williamson et al., *Appl. Environ. Microbiol.*, 60:771-776, 1994). The low level of activity detected by Williamson, et al., *supra* (less than 1 ng/ml), is likely due either to release from lysed cells and a small amount of protein that escapes glycosylation in the *in vitro* system.

As described in Example 1 and Figure 2, we have prepared an altered version of the lysostaphin gene that directs production and secretion of active lysostaphin from mammalian cells. Our first attempt at producing an active, secreted lysostaphin in mammalian cells utilized a construct, pCMV-Lys, in which the coding sequence for mature lysostaphin was operatively linked to the cytomegalovirus promoter and the bovine growth hormone polyadenylation signal. This construct, like that described by Williamson et al., was sufficient to produce lysostaphin in mammalian cells, but did not produce active secreted protein (Figure 3).

In an effort to correct this problem, we produced a second construct, pCMV-hGH-Lys, that included a mammalian signal peptide to direct secretion of the lysostaphin protein from the cell. Those of ordinary skill in the art will appreciate that any of a number of different signal peptides could have been used including, but not limited to, β -lactoglobulin, caseins, erythropoietin, and insulin, so long as they were linked in-frame to the lysostaphin coding sequence. We elected to use the human growth hormone signal peptide, because expression and secretion of the entire human growth hormone gene had previously been demonstrated in the ruminant mammary gland (Kerr et al., *Anim. Biotechnol.* 7:33-45, 1996); moreover, the human growth

hormone signal peptide had previously been used to direct the secretion of engineered proteins from Chinese hamster ovary cells (Pecceu et al, Gene, 97:253-258, 1991).

In analyzing the inactive lysostaphin produced from our second construct, we noted that it had a molecular weight of approximately 33 Kd, somewhat larger than the 5 lysostaphin standard that migrated at 28 Kd (Figure 4). We hypothesized that post-translational processing events, in particular glycosylation events, might be disrupting the activity of the lysostaphin produced in mammalian cells. Other post-translational processing events that might affect biological activity include methylation, disulfide bond formation, acetylation, phosphorylation and sialylation. As those of ordinary skill in the 10 art will appreciate, bacterial proteins are not normally glycosylated. However, when such proteins are expressed in a mammalian system, there is the possibility that the mammalian cell will recognize putative glycosylation steps within the sequence of the bacterial protein, and will add glycosyl groups that may alter the activity of the protein. Glycosylation of lysostaphin during secretion inactivates the lysostaphin protein. 15 Consequently, it may be desirable to modify the potential glycosylation sites to prevent deactivation of the lysostaphin protein by glycosylation during secretion.

We scanned the lysostaphin protein sequence for possible glycosylation sites that might be recognized in a mammalian expression system. We identified two instances of the sequence Asn-X-(Ser/Thr), which can be recognized by mammalian N-linked glycosylation machinery. We confirmed that exposure of the protein to N-glycosidase F, which removes N-linked glycosyl groups, reduced the apparent 20 molecular weight of the protein to that of the lysostaphin standard (Figure 4).

In light of these findings, we prepared new constructs in which we had modified one or both of the N-linked glycosylation sites by substituting Gln for Asn (Figure 2). 25 Those of ordinary skill in the art will recognize that any of a variety of other approaches could be used to disrupt a potential N-linked glycosylation site, but substitution is generally preferred over addition or deletion of residues; conservative substitutions (i.e., substitutions with amino acids of comparable chemical characteristics) are particularly

preferred. For the purposes of conservative substitution, the non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, glycine, proline, phenylalanine, tryptophan and methionine. The polar (hydrophilic), neutral amino acids include serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged 5 (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

We found that removal of both glycosylation sites resulted in production of an active, secreted lysostaphin from mammalian cells (see Example 5 and Example 1). We note that this observation of active lysostaphin secreted from mammalian cells is 10 the first such demonstration. In fact, prior work evidences the difficulty of achieving active secreted protein. In particular, WO 96/35793, reports detection of very large amounts (100 to 250 ng/ml/24 hr) of lysostaphin protein in cell extracts, but little or no activity of that material. Accordingly, an "altered lysostaphin gene" of the present invention is a lysostaphin gene whose sequence has been modified as compared with 15 that of naturally-occurring lysostaphin (SEQ ID NO:3) in that lysostaphin coding sequence sufficient to encode at least mature lysostaphin has been (i) operatively linked to mammalian expression signals sufficient to direct expression of the gene product in mammalian cells; (ii) operatively linked to a mammalian signal peptide such that the expressed gene product is secreted from the mammalian cells in which it is produced, and, preferably, (iii) modified such that at least one, and preferably both, of 20 the Asn-X-(Ser/Thr) N-linked glycosylation sites is disrupted. Alternatively, it may be desirable to eliminate the signal peptide to permit intracellular accumulation of the antimicrobial protein.

As mentioned above, the lysostaphin coding sequence that is useful in the 25 production of altered lysostaphin genes according to the present invention is not limited to the mature lysostaphin sequence; the preprolysostaphin and polysostaphin sequences have also been shown to produce active proteins, although expression of the immature form of lysostaphin is substantially less than that of the mature form.

Moreover, as will be appreciated by those of ordinary skill in the art, various changes to the precise lysostaphin amino acid sequence can readily be made without interfering with (and sometimes promoting, as seen in the glycosylation site examples) lysostaphin activity. So long as the lysostaphin amino acid sequence does not differ so extensively

5 from that presented as SEQ ID NO:2 that activity is lost, the sequence may be used in accordance with the present invention. Those of ordinary skill in the art are well familiar with techniques for modifying amino acid sequences (see, for example, Sambrook, J. et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, N.Y., incorporated herein by reference), and may employ any known technique, including

10 those described herein, to assay the proteins produced from genes containing such modifications in order to determine whether such genes encode functional proteins as required by the present invention. Altered genes that direct expression and secretion of an active lysostaphin protein with one or more sequence differences from naturally-occurring lysostaphin (SEQ ID NO:1) or from the particular altered lysostaphin

15 described herein (SEQ ID NO:3) are considered to be "functional equivalents" of the altered lysostaphin described herein, and are within the scope of the present invention.

Additional modifications to the lysostaphin gene that fall within the scope of the present invention include, for example, nucleotide substitutions that more accurately reflect eukaryotic codon usage without altering the amino acid sequence of the

20 encoded protein (see, for example, Sambrook, et al., *supra*). Such changes are expected to enhance the efficiency of translation and the amount of protein being produced. Another modification involves removal or disruption of a potential polyadenylation signal near the 3' end of the lysostaphin gene.

25 ALTERED β-LYTIC PROTEASE GENES

Another preferred bacterial gene for use in the production of altered genes according to the present invention is the β-lytic protease gene (SEQ ID NO:4) from *Achromobacter lyticus* (Li et al., *J. Bacteriol.*, 172:6506-6511, 1990). β-lytic protease

exhibits potent bacteriolytic activity on *Micrococcus lysodeikticus* and *S. aureus*. It is approximately 25-fold more potent than lysostaphin on heat killed *S. aureus*, and approximately 40-fold more potent than lysostaphin on viable *S. aureus* (Li et al., *J. Biochem. (Tokyo)*, 122: 772-778, 1997).

5 An altered β-lytic protease gene according to the present invention is produced, as was the case with the lysostaphin gene, by operatively linking β-lytic protease coding sequence with (i) a mammalian promoter; (ii) a mammalian translation initiation sequence; and (iii) a mammalian signal peptide. Additional modifications may also be made.

10

OTHER ALTERED GENES

Any of a variety of other genes encoding agents with anti-microbial activity may also be employed in accordance with the present invention. As discussed above, a variety of different microbial anti-staphylococcal agents are known. Any gene encoding such an agent may be modified as described herein to produce an altered gene of the present invention. Useful genes may be isolated from any natural source, including bacteria, fungi, plants, and other microbes.

These other anti-staphylococcal genes are modified to produce altered genes of the present invention through operative linkage with (i) a mammalian promoter; (ii) a mammalian translation initiation sequence; and (iii) a mammalian signal peptide. Additional modifications may also be made. For example, some such genes may have introns, or sequences that are recognized as introns, that are inappropriately spliced in a mammalian system. Such inappropriate splicing events can be identified, for example, by isolating mRNA from a mammalian cell transfected with a version of the gene that has been modified to include the mammalian promoter, translation initiation sequence, and signal peptide. Inappropriate splicing may be corrected by alteration of inappropriate splice sites, or removal of intronic sequences. However, it is often desirable to maintain (or introduce) at least one intron in an altered gene, as intron-

containing genes are often more efficiently expressed in mammalian systems (see, for example, Wall and Seidel, *Theriogenology*, 38:337-357).

Also, the mammalian signal peptide might not be properly cleaved from the protein produced upon expression of a modified gene containing a mammalian promoter, translation initiation sequence, and signal peptide in a mammalian cell.

Inappropriate signal peptide cleavage may be identified by immunopurification of the expressed protein, which is then analyzed by polyacrylamide gel electrophoresis and/or N-terminal sequencing. Problems with signal peptide cleavage can generally be corrected through selection of a different signal peptide, such as one from one of the major milk proteins.

Additionally, as discussed above, modifications may be made to introduce mammalian codons without changing protein sequence, to remove or disrupt any putative glycosylation sites and/or polyadenylation signals, etc.

Finally, those of ordinary skill in the art will recognize that the principles taught by the present invention are readily applicable to genes encoding proteins or peptides with anti-microbial (including anti-viral) activity other than, or in addition to, anti-staphylococcal activity. For example, as mentioned above, *Staphylococcus aureus* accounts for up to only 30% of intra-mammary infections (Nickerson et al, *J. Dairy Sci.*, 78:1607-1618, 1995). It will be clear to one skilled in the art that the other 70% of intra-mammary infections are due to other pathogens and therefore any protein with anti-bacterial activity that would combat the offensive pathogen could be delivered to the mammary gland for treatment of mastitis. Furthermore, multiple genes could be delivered to the mammary gland simultaneously (see further discussion below).

25 *Introduction of Altered Genes into Mammalian Expression Systems*

The altered anti-microbial genes of the present invention may be introduced into mammalian cells or tissues in order to treat or prevent infection of those tissues. *In vitro* transfection methods that introduce DNA into mammalian cells in culture are well

known in the art, and include calcium phosphate transfection, DEAE-dextran transfection, electroporation, and liposome-mediated transfection.

In the present invention, it is preferred that the method of protein expression utilize methods that transfer DNA into living cells *in vivo*. In certain embodiments, the genes are delivered by somatic cell engineering, or gene therapy. In such circumstances, the genes are not delivered to the animal's offspring, and are often (unless retroviral delivery systems are employed) only transiently expressed in the cells to which they are delivered.

A variety of systems are available for delivering altered genes to somatic cells, either systemically or locally, in accordance with the present invention (see, for example, Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates, New York, V. 1&2, 1996 and Kerr et al., *Anim. Biotechnol.*, 7:33-45, 1996).

Such systems include, but are not limited to, high-pressure jet injection, liposome-based delivery systems, and viral delivery systems, including both retroviral and standard viral systems.

The mammalian cells and tissue into which altered genes of the present invention are to be produced include any mammalian cells or tissues. Preferred cells are tissues within ruminants such as cows, sheep and goats, but also include human tissues. Also, although mammary tissue is one particularly preferred tissue for expression (see below), any tissue that is susceptible to, or that is experience, microbial infection, is a desirable expression site according to the present invention.

Notwithstanding the foregoing, expression in mammary tissue is a particularly preferred aspect of the present invention. Thus, in preferred embodiments of the invention, the delivery system is selected, in combination with the gene modifications, to ensure that the altered gene is expressed in mammary tissue. In one particularly preferred embodiment, an altered anti-staphylococcal gene is delivered locally to mammary epithelial cells via the teat canal. This route of intramammary infusion administration has the greatest chance of transfecting the epithelial cells lining the teat

or teat duct, which are a prime target for attachment and invasion by staphylococcal species and therefore are also an important target for the production of anti-microbial proteins. Alternatively, in another preferred embodiment delivery of plasmid DNA into lactating sheep mammary parenchyma can be achieved by high-pressure jet-injection.

5 This method achieves transfection of cells within the narrow path of the injectate (Kerr et al., *Anim. Biotechnol.*, 7:33-45, 1996).

Altered anti-staphylococcal genes can be delivered to the epithelial cells of the mammary gland by non-viral approaches (Hyde et al., *Nature*, 362:250-255, 1993; Oudrhiri et al., *Proc. Natl. Acad. Sci. U.S.A.*, 94:1651-1656, 1997; Hens et al., *Molec. 10 Bio1. of Cell, Suppl.*, 1996). Non-viral approaches generally rely on liposome carriers to enhance transfection efficiency. For example, transfection of guinea pig mammary gland with the human growth hormone gene resulted in accumulation of up to 500 ng/ml of the human growth hormone in milk (Hens et al., *supra*).

In other preferred embodiments of the present invention, viral vector approaches are utilized to achieve transient transfection of mammary epithelial cells with inventive altered genes. Viral vector approaches include retro- (Kay et al., *Science*, 262:117-119, 1993), adeno- (Smith et al., *Nat. Genet.*, 5:397-402, 1993) and adeno-associated viruses (Flotte, *J. Bioener. Biomembr.*, 25:37-42, 1993). Retrovirus infection results in integration of the viral nucleic acid code into the host cell DNA, causing permanent transfection of that cell. Retroviruses can only infect dividing cells, but have been shown to be capable of transfecting the caprine mammary gland during a period of hormone-induced mammogenesis (Archer et al., *Proc. Natl. Acad. Sci. U.S.A.*, 91:6804-6844, 1994). In a particular preferred embodiment, an adenovirus vector is used to deliver altered anti-staphylococcal genes to bovine mammary 20 epithelial cells. The adenoviral-based method of gene delivery has several advantages over retroviral-based gene delivery in that transfection efficiency is higher, and it can infect non-dividing cells. New adenoviral vectors have also been developed that limit 25 the host antiviral immune response which is common to adenoviral transfection. A

strong cellular immune response can greatly reduce the persistency of adenoviral-mediated gene expression and precludes repeated administration of the same vector (Ilan et al., *Proc. Natl. Acad. Sci. U.S.A.*, 94:2587-2592, 1997; Chen et al., *Proc. Natl. Acad. Sci. U.S.A.*, 94:1645-1650, 1997; Smith et al., *supra*). We have
5 demonstrated that an adenoviral vector systems can be successfully employed for delivery of genes to the ruminant mammary (Plaut et al, *J. Dairy Sci.*, 80, Suppl. 1, 155 (Abstract), 1997) (see Example 2). Direct administration of adenovirus containing the β-galactosidase gene to the teat of a goat resulted in intense blue staining of the entire lining of the teat canal (see Figure 7). Mammary tissues were also infected. This
10 finding is readily generalizable to the inventive altered genes, which may therefore also be delivered to ruminant mammary cells through adenoviral transfection (see Example 3).

Those of ordinary skill in the art will appreciate that it will sometimes be desirable to express more than one inventive altered gene simultaneously in the same
15 mammalian cells or tissue. With this multi-gene approach, not only is the spectrum of the bactericidal activity improved, but the likelihood of bacterial resistance development is substantially diminished.

Transgenic Animals

The altered genes of the present invention may also be introduced into mammalian cells through transfer into mammalian germ line cells and subsequent production of transgenic animals. Established methods for such germ line transfer include, but are not limited to, micro injection of DNA into one-cell embryos (Gordon et al., *Proc. Natl. Acad. Sci U.S.A.*, 77:7380-7384, 1980), transfer of genetically
20 engineered embryonic stem-cells into blastocysts (Hooper et al, *Nature*, 326:292-295, 1987; Kuehn et al, *Nature*, 326:295-298, 1987), and the transfer of nuclei from engineered cells into enucleated oocytes (Campbell et al, *Nature*, 380:64-66, 1996). Germ genetically engineered cells to oocytes, (Schnieke et al., *Science*, 278:2130-
25

2133, 1997) results in a permanent change in the animal's genome, and the genomes of its offspring.

Germ cell engineering has become wholly routine in the area of transgenic mice (Gordon et al., *Biotechnology*, 5:1183-1187, 1987), and has also been broadly applied
5 to pigs (Wall et al., *Proc. Natl. Acad. Sci. U.S.A.*, 88:1696-1700, 1991), sheep (Wright et al., *Biotechnology*, 9:830-834, 1991), goats (Ebert et al., *Biotechnology*, 9: 835-838, 1991), and cattle (Krimpenfort et al., *Biotechnology*, 9:844-847, 1991). To give but one relevant example, Gordon et al., (*Biotechnology, supra*) have created transgenic mice that produced human tissue plasminogen activator in transgenic mouse milk. Any of
10 the techniques described in these references, or otherwise known in the art, may be employed to create transgenic animals in which an altered gene of the present invention has been stably introduced into their genome. Such transgenic animals are useful not only as staphylococcus-resistant creatures, but as bioreactors for the production of anti-staphylococcal agents for use in the treatment of others.

15

Peptide Antibiotics

Peptide antibiotics are widespread in nature, being found in plants, animals and prokaryotes. Animal antibacterial proteins include lysozyme, lactoferrin, and a class of antimicrobial compounds known as defensins. Lysozyme is a muramidase to which
20 Gram negative and some Gram positive microorganisms such as *S. aureus* show varying degrees of resistance (for reviews, see Reiter, et al., *International Dairy Federation Bulletin #191 IDF*, Square Vergote 41, 1040 - Brussels, Belgium; Magga and Murray, *J. Dairy Sci.*, 78:2645-2652, 1995). It is normally present in human milk at approximately 100 µg per ml and in ruminant milk at less than 1 µg per ml, yet the role
25 lysozyme may play in the prevention of mastitis is presently unknown. However, lactoferrin, which acts as an antimicrobial through its iron-chelating activity, (Reiter et al, *supra*), does protect the non-lactating mammary gland from infection by *E. coli*, although this inhibition is lost at the time of calving (Bramley, *J. Dairy Res.*, 43:205-211,

1976). Furthermore, the defensins, produced in neutrophils, macrophages and epithelial cells lining mucosal surfaces (Kagan et al., *Toxicology*, 87:131-149, 1994), also have antibacterial action resulting from their ability to form pores in susceptible cellular membranes. One particular defensin, bovine tracheal antimicrobial peptide, 5 (TAP), has antibacterial activity *in vitro* against *E. coli* and *S. aureus*, with minimum inhibitory concentrations (Diamond et al., *Proc. Natl. Acad. Sci. U.S.A.*, 88:3952-3956, 1991) and would therefore be a likely candidate for use in the present invention.

Examples

10 The present invention can be further understood through consideration of the following non-limiting Examples.

Example 1

Genetic Engineering of the Lysostaphin Gene

A. Construction of new lysostaphin expression plasmids

15 In an attempt to increase production and secretion of lysostaphin four new expression constructs were prepared (Figure 2). All four constructs were made by inserting modified lysostaphin genes into the polylinker of the 5.4 Kb eukaryotic expression vector, pcDNA3 (Invitrogen). The vector contains the CMV promoter and the bovine GH polyadenylation signal, with an intervening polylinker.

20 All four lysostaphin constructs were generated by a PCR-based technique in which the 5' primer included a 5' Not I restriction site and the 3' primer included a 3' Apa I site. The primers were positioned such that only the coding region and the TGA stop codon of the mature portion of the lysostaphin gene were amplified. We used pCMLEM (Simmonds et al., *Appl. Environ. Microbiol.*, 62:4536-4541, 1996) as the lysostaphin template, and the resulting Not I - Lysostaphin - Apa I amplicons were cloned between the Not I and Apa I sites in the pcDNA3 polylinker. The nucleotide sequences of all PCR-generated fragments were confirmed with an automated cycle-sequencing technique at the University of Vermont molecular diagnostics laboratory.

The expression plasmid pCMV-Lys was constructed by inserting a short linker sequence 5' to the mature lysostaphin sequence, between the Bam HI and Not I sites of the pcDNA3 polylinker. The short sequence was prepared from two custom 13 base oligonucleotide (Gibco/BRL), and resulted in the addition of a Kozak sequence and a 5 start codon (ATG) to the lysostaphin gene. These features, that are required for efficient translation initiation, encode the insertion of an additional N-terminal amino acid (methionine) to the lysostaphin protein. This engineered protein does not contain a signal peptide and thus would not be transferred to the golgi apparatus for glycosylation and secretion.

10 The expression plasmid pCMV-hGH-Lys was constructed by inserting the human growth hormone (hGH) intron-containing signal peptide coding region, 5' to the mature lysostaphin sequence. This eukaryotic signal peptide was chosen to enhance the secretion of lysostaphin from the cells. We have previously had satisfactory experience with the expression of the entire hGH gene in the ruminant mammary gland (Kerr et al.,
15 *Anim. Biotechnol.*, 7:33-45, 1996), and it has been used by others to direct the secretion of engineered proteins (Pecceu et al., *Gene*, 97:253-258, 1991). The coding region of the hGH signal peptide included the 5' untranslated region and the first intron of the hGH gene. The intronic sequence was included as there is good evidence that introns increase expression of foreign proteins (Wall and Seidel, Jr., *Theriogenology*,
20 38, 337-357, 1992). The modified hGH signal peptide was obtained from a collaborator (Dr. K. Wells, GEML-ARS-USDA, Beltsville, MD). The resulting hGH-lysostaphin sequence codes for the amino acids of the entire hGH signal peptide immediately followed by the entire mature form of lysostaphin. The sequence of this construct was confirmed by DNA sequencing.

25 The expression plasmids pCMV-hGH-Lys-ΔGly2 and pCMV-hGH-Lys-ΔGly1-ΔGly2 were subsequently prepared. A PCR strategy was used to remove glycosylation sites from the mature lysostaphin gene and generate pCMV-hGH-Lys-ΔGly2 and pCMV-hGH-Lys-ΔGly1-ΔGly2. pCMV-hGH-Lys-ΔGly2 removes one of two potential N-

linked glycosylation sites within mature lysostaphin. The final construct, pCMV-hGH-Lys- Δ Gly1- Δ Gly2, was designed to encode a lysostaphin protein in which both N-linked glycosylation sites (Asn-X-Ser/Thr) have been removed by mutation of the site's Asn codons to Gln codons (Figure 2). Bacterial proteins are not normally glycosylated, but
5 when expressed in a eukaryotic system, any Asn-Xxx-Ser/Thr sequence of amino acids in a protein has the potential for N-linked glycosylation. The plasmids pCMV-hGH-Lys- Δ Gly2 and pCMV-hGH-Lys- Δ Gly1- Δ Gly2, was constructed in a similar fashion to pCMV-hGH-Lys. However, the 3' primer for generating the lysostaphin amplicon contained nucleic acid substitutions that resulted in a change from AAT to CAG at the codon for
10 amino acid number 232 of the mature lysostaphin protein. This causes an asparagine to glutamine change in the encoded protein, and thus destruction of the potential glycosylation site. We chose to convert Asn to Gln based on the similar structure and characteristics of their side groups. The plasmid pCMV-hGH-Lys- Δ Gly1- Δ Gly2 was similarly constructed using a synthetic 5' primer. The Asn to Gln strategy was recently
15 reported as being successful in preventing the glycosylation of a bacterial enzyme that was engineered to be expressed on the cell surface of eukaryotic cells (Marais et al., *Nat. Biotechol.* 15:1373-1377, 1997). Importantly, these authors reported considerable enzymatic activity of the modified protein was maintained, even with three Asn to Gln mutations.
20

B. *Evaluation of lysostaphin expression plasmid in vitro*

Lysostaphin expression from the four new constructs was evaluated following their transfection into COS-7 cells. The cells were transfected in six-well culture plates, with a CaPO₄ precipitation technique (Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, N.Y., 1989, incorporated herein by reference). Following exposure to the plasmid precipitate, cells were washed and then incubated with 1 ml DMEM containing 10% FBS for 48 hr Media was then collected, cleared by centrifugation and stored (-20 C°). Cell extracts were obtained by freeze/thaw

disruption of the cell monolayer with 0.5 ml phosphate buffered saline (PBS). Transfection efficiency was monitored visually by co-transfection with a green fluorescent protein expression plasmid. The plasmid, pCMV-GFP, was constructed by inserting the GFP encoding fragment from pEGFP-NI (Clontech) into pcDNA3. Plasmid 5 DNA used in transfections contained a 9:1 mixture of the test plasmid and pCMV-GFP. Consistently high (>50%) transfection efficiencies were obtained (Figure 7F).

Cell extracts from COS-7 cells transfected with the signal peptide devoid construct, pCMV-Lys, exhibited bacteriolytic activity using plate assay technique (Figure 10 3 and 5). For the plate assay, aliquots of the cell extract or conditioned media were spotted onto culture plates that had been freshly streaked with *S. aureus* (strain M60). Following an overnight incubation clear lytic zones were observed. We estimated the lysostaphin concentration to be \approx 50 ng/ml by comparison with standard preparations containing a commercial lysostaphin preparation (Sigma L-7386). No activity was detected in media, presumably because the lysostaphin gene lacked a signal peptide.

15 No activity was detected in media or cell extracts from cells transfected with a control plasmid, pCMV-hGH. Thus, the COS-7 cells are capable of producing lysostaphin, and it appears to be non-toxic.

Lysostaphin bioactivity was not detected using the *S. aureus* plate assay, in either media or cell extracts from COS-7 cells transfected with pCMV-hGH-Lys. 20 However, substantial lysostaphin immunoreactivity was observed by western blot assay of media but not extracts of cells transfected with p pCMV-hGH-Lys (Figure 6, lane 4). The band migrated with an apparent molecular weight of \approx 33 Kd, somewhat larger than the lysostaphin standard that migrated at \approx 28 Kd. Media samples were estimated to contain \approx 200 ng/ml of immunoreactive lysostaphin. To determine if the larger 25 molecular weight of the engineered protein was due to N-linked glycosylation, samples were deglycosylated by overnight incubation with N-glycosidase-F (Boehringer-Mannheim). A clear reduction in the apparent molecular weight of the expressed protein to that of the lysostaphin standard was observed (Figure 4, lane 5). Thus,

addition of the hGH signal peptide region to pCMV-Lys directed the secretion of relatively large quantities of a glycosylated inactivated lysostaphin protein by COS-7 cells. The 26 amino acid signal peptide, which has a predicted molecular weight of 2.7 Kd, was apparently cleaved, as the deglycosylated protein had a similar molecular

5 weight to the lysostaphin standard.

Transfection with the pCMV-hGH-Lys- Δ Gly2 construct did not result in the desired increase in activity or size reduction of COS-7 produced lysostaphin. The media, but not cell extracts, obtained from these transfections contained similar levels of similar sized immunoreactive lysostaphin as those resulting from pCMV-hGH-Lys

10 transfections (Figure 6, lane 6).

Transfection of the eucaryotic cell line, COS-7, with the pCMV-hGH-Lys- Δ Gly1- Δ Gly2 construct, that encodes a lysostaphin protein in which both N-linked glycosylation sites have been removed reveals bioactive lysostaphin in the culture media but not in the cell extracts (see Figure 5). Strong, yet indirect evidence for secretion of the protein rather than cell lysis and release into media is found by comparison of results obtained from the signal peptide devoid construct pCMV-Lys, and the new construct containing the hGH signal peptide, pCMV-hGH-Lys. Without the signal peptide, lysostaphin accumulates within the cells such that cell extract, but not media cause bacterial lysis. This media likely does contain some lysostaphin resulting from cell lysis, but the concentration is below the detection limits of our assay. However, with the hGH signal peptide, and the deglycosylation construct, bioactive lysostaphin is detected only in media, not in cell extract. Presumably the cell extract contains an amount of bioactive lysostaphin that is below detection. No bioactivity is observed from cells transfected with the construct containing the hGH signal peptide and the unmodified lysostaphin gene.

Example 2

Adenovirus Mediated Expression of β -galactosidase

Express Mail No. EE441114555US
3183367_1.DOC

A. *Propagation of Av1LacZ4*

The plasmid Av1LacZ4, (Genetic Therapy Inc; Bethesda, MD), is a replication deficient, recombinant, human type 5 adenovirus that contains the gene for nuclear targeted β -galactosidase (LacZ) (Smith et al., *supra*). The E3 region of this adenovirus
5 has been deleted and the β -galactosidase gene replaces the E1a region rendering the virus replication incompetent. Viral stocks were prepared using the 293 packaging cell line (ATCC #CRL-1573). This cell line is a stable transfectant that produces the Ad 5
E1a transcription factor and thus complements the E1a deletion in the recombinant
virus. Briefly, confluent 293 cells were infected with the virus and 36 hr later the
10 propagated virus particles recovered by 5 cycles of freeze/thawing. A cleared lysate was obtained by low speed centrifugation, and a purified preparation was obtained following two rounds of CsCl density-gradient ultracentrifugation. The CsCl was removed by extensive dialysis against sterile 10 mM Tris pH 7.4, 1 mM MgCl₂, 10% glycerol. Viral stocks were stored at -70 C°. Titres of the viral stocks were determined
15 by plaque assay using 293 cells.

B. *Infection of a ruminant cell line with Av1LacZ4*

To confirm integrity of our viral stocks and to ensure that the human Ad5 would infect ruminant cells, a bovine mammary epithelial cell line, BME-UV clone E-T2
20 (Zavizion et al., *In Vitro Cell Dev. Biol. Anim.* 32:138-148, 1996) was exposed to Av1LacZ4 (10 pfu/cell). After 48 hr the cells were fixed and stained for β -galactosidase activity using the X-Gal reagent. The infection was successful (Figure 7E).

C. *Infection of the goat mammary gland in vivo*

25 Goats were exposed to Av1LacZ4 to evaluate the ability of the human adenovirus to infect the ruminant mammary gland *in vivo*. Two mature virgin, and three multiparous goats, that had been non-lactating for three months, were infused with the LacZ containing adenovirus. One teat of each goat was infused with 1 ml of a solution

(10 mM Tris pH 7.4, 1 mM MgCl₂, 10% glycerol) containing Av1LacZ4 (1.9×10^{10} pfu/ml). The contralateral teat acted as control being infused with vehicle. A similar set of infusions was administered 48 hr later but the concentration of virus was reduced to 0.6 pfu/ml. The animals were euthanized 24 hr later.

5 Teat tissue and mammary tissue samples adjoining the base of the teat were fixed in 2% paraformaldehyde - 020.% glutaraldehyde and processed for detection of β -galactosidase activity (Furth et al., *Molecular Biotechnology*, 4:121-127, 1995). Intense blue staining of the entire lining of the teat canal was observed (Figure 7A). Histological sections revealed that the infection was limited to the luminal cell layer (Figure 7C).

10 Mammary tissues were also infected (Figure 7B).

Primary cultures of mammary tissues were prepared by collagenase digestion and plating on plastic culture dishes. After 24hr incubation in DMEM containing 10% FBS in a 5% CO₂ atmosphere, the cultures were fixed and stained with X-Gal. Infected mammary epithelial cells were observed (Figure 7D). There was no staining visible in tissues or cells from vehicle infused glands.

15 *D. Characterization of adenoviral-mediated transfection of the goat mammary gland*

In order to continue to explore adenoviral transfection of the goat mammary gland the β -galactosidase-containing adenovirus, Av1LacZ4 is used. These studies are conducted with two, non-lactating multiparous goats / treatment similar to the experiment described above. First, the dose response characteristics using a single infusion of adenovirus is explored. Goats are infected with a single, 1 ml infusions of 20 1.0×10^{11} , 1.0×10^{10} , 1.0×10^9 and 1.0×10^8 pfu/ml. Contralateral glands received 25 vehicle alone. These doses are based upon previous results. Mammary secretions are obtained prior to, and at 24 hr and 48 hr post-infusion. The goats are euthanized 48 hr post-infusion. Evaluation of the infections include monitoring animal health

(temperature, respiration, rumination, and post-mortem evaluation) and determining SCC and the presence of bacterial infection.

Transfection is evaluated by staining teat and mammary tissues with X-gal reagent and then evaluating them grossly and microscopically. Histopathology is also evaluated. Infusions of 1.9×10^{10} and 0.6×10^{10} pfu/ml are administered 72 hr and 24 hr prior to euthanasia, respectively. A minor inflammatory response may develop as evidenced by fluid accumulation in the gland and an elevation in somatic cell count. Rectal temperatures are monitored. Secretions are examined for bacterial contamination. This characterization allows determination of the lower dose of adenovirus that will ameliorate these symptoms, and yet still provide adequate transfection.

E. Adenoviral-based transfection of the goat mammary gland with an engineered lysostaphin construct.

Adenoviral-based transfection of the goat mammary gland *in vivo* has been undertaken as with the Av1LacZ4 infections. Each of two multiparous non-lactating goats were infected in one gland by intramammary teat infusion with the lysostaphin-containing adenovirus. The contralateral gland was infused with the LacZ-containing adenovirus. The goats were euthanized 48 hr post-infusion. Mammary secretions were collected prior to infusion, and at 24 hr and 48 hr post-infusion. Secretions and tissues from the glands were processed as previously described with additional measurements for lysostaphin production and activity as follows.

Secretions from the glands, and extracts prepared from tissue fragments, were assayed for immunoreactive lysostaphin using western blot and an ELISA that have been developed. Prior to assay, sample infranatants were prepared by two sequential centrifugation steps (15 min, 12,000g, 4 C°), in which the fluid between the fat layer and pelletable protein and debris was harvested. All secretions were normalized based upon total protein content, determined by a modification of the Lowry method (Nerurkar

et al., in Manual of Macrophage Methodology, (H.B. Herscowitz et al, eds.) New York: Marcel Dekker, Inc., pp. 229-246, 1981). Recovery of standard lysostaphin added to samples prior to processing was determined. At 48 hr post-infusion, the secretions collected from the two glands infused with the lysostaphin adenovirus contained 860
5 ng/ml and 1100 ng/ml, respectively, of lysostaphin. No lysostaphin was detected in the secretions from the contralateral glands infused with the lacZ-adenovirus.

Lysostaphin production is also evaluated in tissue sections processed for immunohistochemistry using our rabbit polyclonal antibody to lysostaphin.
10 Immunohistochemical techniques are currently available. Briefly, formalin fixed tissue is embedded in paraffin, and sectioned (6 µm) by the UVM histology core facility. Slides are then deparaffinized and rehydrated. Endogenous peroxidase are blocked by a 10 min incubation with 0.3% hydrogen peroxide in methanol. Non-specific protein binding is blocked with a 30 min incubation in 10% normal goat serum in 1% BSA-PBS.
15 Sections are be incubated for 60 min with 10 µg/ml of our rabbit polyclonal antibody generated against lysostaphin. Bound antibody is detected with biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA) subsequently coupled to streptavidin-peroxidase. Then the chromogen, amino ethyl carbazole (AEC) and the substrate (0.6% peroxide) are added to the sections allowing the development of a red color
20 (Zymed Laboratories, San Francisco, CA). Negative controls are incubated with the primary antibody in the presence of a 100 fold excess of a lysostaphin.

Methods for adenoviral-based transfection of the lactating goat mammary gland are also available. Briefly, experiments are conducted, similar to those described above, during the sixth week of established lactation. Kids are used to initiate and maintain lactation, but are be replaced by hand milking during the viral infusions. Milk is
25 removed from glands immediately prior to adenoviral infusion. Oxytocin is administered to ensure let-down. One gland is infused with Av1LacZ4, the other with the lysostaphin containing adenovirus. Initial dose response experiments, conducted with two goats / dose, are undertaken to evaluate transfection during lactation. These experiments are

48 hours in duration. Subsequent longer duration experiments are conducted with a dose determined from previous experiments.

Example 3

5 Adenovirus Mediated Expression of Lysostaphin

A. Construction of Adenoviruses containing lysostaphin genes

GTI supplied start up quantities of an E3 region deletion mutant (AD5-d327) of the AD5 adenovirus, and the shuttle plasmid pAvS6(Smith et al., *supra*) that was used to construct the recombinant adenoviruses carrying the lysostaphin gene. The Not I-

10 Kpn I fragment of the shuttle plasmid contains the inverted terminal repeat and encapsidation signal from the left end of AD5-d327, the RSV promoter, a multi-cloning region for insertion of the gene of interest, the SV40 Poly (A+) signal, and Ad5 sequences from nucleotide 3328 to 6246 that serve as a homologous recombination region.

Two shuttle plasmids were constructed. One, named pAvS6-preprolys, was constructed by inserting the 1.5 Kb modified lysostaphin gene from pCMLEM (Williamson et al., 1994) into the pAvS6 shuttle vector. This modified lysostaphin gene contained a Kozak region linked to the preprolysostaphin gene. The other called pAvS6-hGH-Lys- Δ GLY1- Δ GLY2 contained the human growth hormone signal peptide linked to the modified lysostaphin construct which was obtained from pCMV-hGH-Lys- Δ GLY1- Δ GLY2.

The shuttle plasmids, pAvS6-preprolys, and pAvS6-hGH-Lys- Δ GLY1- Δ GLY2 were independently used to generate two recombinant adenoviruses, Ad-preprolys and Ad- hGH-Lys- Δ GLY1- Δ GLY2, respectively. The recombinant viruses were constructed by co-transfection of the linearized shuttle plasmids with the Cla I fragment of Ad5-dl327 into 293 cells. Resulting plaques were purified. Insertion of the lysostaphin genes into the viral genomes was confirmed by polymerase chain reaction.

B. Evaluation of lysostaphin production by COS-7 cells infected with Ad-preprolys

Near confluent cultures of COS-7 cells were exposed to a cleared cell lysate from 293 cells that had been infected with Ad-preprolys to evaluate lysostaphin production. Samples of culture media and cell extracts were prepared from the infected 5 COS-7 cells 48 hr after infection. Lysostaphin production was evaluated by an SDS-PAGE - western blotting technique using a rabbit polyclonal antibody to lysostaphin (Figure 3). The antibody was prepared for us by R. Sargent Inc. (Ramona, CA) using affinity purified lysostaphin (Sigma L-4402). Samples (50 µl) were denatured by boiling in the presence of a β-mercaptoethanol-containing loading buffer and electrophoresed 10 through a 1.5 mm thick, 12 % polyacrylamide gel for 4 hrs (Protean II apparatus; Bio-Rad). Proteins were then transferred to nitrocellulose for immunodetection. Bound anti-lysostaphin antibody was detected with an alkaline phosphatase-linked second antibody (Sigma) and BCIP/NBT reagent (Bio-Rad). Cell extract from Ad-preprolys infected COS-7 cells contained a detectable quantity, of immunoreactive lysostaphin 15 that migrated with an apparent molecular weight of ≈ 90 Kd (Figure 3, lane 10). This molecular mass is very similar to that previously observed by Williamson et al. (1994) following introduction of a similar lysostaphin construct using a plasmid based calcium phosphate transfection protocol. The protein is likely preprolysostaphin. Mature lysostaphin migrates with an apparent MW of ≈ 28 Kd (Figure. 3, lanes 7, 8) The 20 lysostaphin derived from Ad-preprolys infected COS-7 cells was apparently not secreted as it was not detectable in the corresponding media sample (Figure 3, lane 11). No bioactivity was detected in media or cell extracts from Ad-preprolys infected COS-7 cells.

25 C. Evaluation of lysostaphin production by 293 cells infected with Ad- hGH-Lys-

ΔGLY1-

Δ GLY2

Lysis of *S. aureus* (M60) by bioactive lysostaphin produced by 293 cells infected with Ad- hGH-Lys-□GLY1- □GLY2 was evaluated by plate assay. Samples (60 µl) or standards (15 µl) were added to a LB agar plate freshly streaked with *S. aureus*. Results were evaluated following a 12 hour incubation at 37 °C. Lysostaphin standards 5 were prepared in media. The concentrations were 3 ng/µl, 30 ng/µl and 100 ng/µl. Inhibition of *S. aureus* growth was observed by the standard preparations and by culture media obtained from 293 cell cultures that had been infected with Ad- hGH-Lys-△GLY1-△GLY2. These results are illustrated in Figure 1.

10

Example 4

Production and Evaluation of Transgenic Mice Incorporating the Lysostaphin Gene under Control of a Mammary Specific Promoter.

This model allows assessment of the functionality of the transgene when incorporated into the genome of an animal, determination of toxicity of the transgenic protein to the lactating mammary gland, and assessment of the effects of the transgene on milk production. The antibacterial properties of milk from these animals can also be measured. A variety of mammary gland and lactation specific promoter regions could be used to direct expression of the lysostaphin gene to the lactating mammary gland. These include, but are not limited to, the regulatory sequences of the casein genes, whey acidic protein, and - lactoglobulin. We chose to use the - lactoglobulin regulatory sequence.

The 4.2 Kb 5'-flanking (promoter) region and 2.1 Kb of the 3-flanking region of the ovine -lactoglobulin (BLG) gene (pBJ41) were obtained from Dr. A.J. Clark (Roslin Institute, UK). These components have been used to direct the production of mg/ml 25 concentrations of foreign proteins into the milk of mice (Archibald et al., *Proc. Natl. Acad. Sci. USA* 87, 5178-5182, 1990) and sheep (Wright et al., *Bio/technology* 9, 830-834, 1991). The 1.4 Kb modified lysostaphin gene containing the hGH signal peptide was excised from pSec-Lys-G1n2 and inserted into pBJ41 between the 5- and 3-

components of the BLG gene. The entire 7.7 Kb fusion gene (BLG-Sec-Lys-Gln2) was then excised and purified for microinjection. Nine founder transgenic mice were produced in the laboratory of Dr. R.J. Wall (USDA-ARS-GEML; Beltsville, MD) using standard techniques. Five lines of mice have now been established. These mice appear
5 normal, are fertile, and are able to raise offspring. To date, milk has been obtained from F1 mice representing three of the lines. The milk was collected on day 10 of lactation (Maga et al., *J.Dairy Sci.* 78: 2645-2652, 1995). The milk samples were immediately frozen (-80 °C) and then shipped to our laboratory on dry ice.

Milk was analyzed for lysostaphin immunoreactivity as described for cell culture
10 experiments. Prior to analysis milk samples were diluted (1:10) in PBS containing 0.5% BSA, then defatted by centrifugation (15 min, 4, 10,000 g). Western blot analysis of milk from three different BLG-Sec-Lys-Gln2 -transgenic mice (#16797, #16796, #16775) revealed a very intense lysostaphin band (Figure 9). The migration distance appears identical to the lysostaphin standard.

15 Milk from another BLG-Sec-Lys-Gln2 -transgenic mouse (#16755) contained substantial staphylocolytic bioactivity (Figure 10). The lytic zones that developed from a dilution series of milk indicated that a 1:1,600 dilution of milk contained an amount of bioactivity equivalent to between 125 ng/ml and 250 ng/ml of lysostaphin standard (Sigma).

20

Example 5

Transgenic Ruminants

The present invention provides transgenic dairy cows containing a modified lysostaphin gene, although the cost and duration of such an endeavor necessitates
25 preliminary experiments using the much less expensive, and more rapid, transgenic mouse model.

A. *Production of Non-Rodent Transgenic Animals*

Express Mail No. EE441114555US
3183367_1.DOC

Procedures for the production of transgenic non-rodent mammals and other animals have been discussed by others (see Houdebine and Chourrout, *supra*; Pursel *et al.*, *Science* 244:1281, 1989; and Simms *et al.*, *Bio/Technology*, 6:179, 1988). Such procedures can be applied to an altered gene of the present invention to produce
5 transgenic dairy cows expressing lysostaphin (see Krimpenfort *et al.*, *Biotechnology*, 9:844-847, 1991, incorporated herein by reference). If expression is desirably limited to mammary tissues, a mammary-specific promoter may be employed.

Other Embodiments

10 One of ordinary skill in the art will readily recognize that the foregoing represents merely a detailed description of certain preferred embodiments of the present invention. Various modifications and alterations of the genes and uses thereof described above can readily be achieved using expertise available in the art, and are within the scope of the following claims.
15

Claims

We claim:

- 5 1. A nucleic acid comprising a modified gene encoding an anti-microbial protein
wherein the coding sequence is from the natural host, but has been modified to allow
expression of the active form.
- 10 2. The gene of claim 1 wherein the modified gene is operatively linked to at least
one mammalian regulatory sequence.
- 15 3. The gene of claim 1 wherein the modified gene contains mutations that eliminate
one or more glycosylation sites.
- 20 4. A modified gene comprising a gene encoding lysostaphin, wherein the
lysostaphin gene has been modified to allow expression of the active form of
lysostaphin.
- 25 5. The gene of claim 4 wherein the modified gene is operatively linked to at least
one mammalian regulatory sequence.
6. The gene of claim 4 wherein the modified gene is operatively linked to at least
one mammalian regulatory sequence and contains mutations that eliminate one or
more glycosylation sites.
7. The gene of claim 4 wherein the modified gene is operatively linked to at least
one mammalian regulatory sequence and contains mutations that eliminate both
glycosylation sites

8. The gene of claim 4 wherein the gene encoding lysostaphin comprises preprolysostaphin.
- 5 9. The gene of claim 4 wherein the gene encoding lysostaphin comprises prolysostaphin.
10. The gene of claim 4 wherein the gene encoding lysostaphin comprises mature lysostaphin.
- 10
11. A nucleic acid comprising a gene encoding lysostaphin that is biologically active when expressed in mammalian cells.
- 15 12. The gene of claim 11 wherein the gene encoding lysostaphin is modified as compared with SEQ ID NO: 3, modifications selected from the group consisting of:
at least one mammalian regulatory sequence operatively linked to the lysostaphin coding region; and
removal of at least one glycosylation site.
- 20 13. The gene of claim 11 wherein the gene encoding lysostaphin is modified as in SEQ ID NO: 3 which comprises:
a eukaryotic start codon;
the Kozak expression start site consensus sequence;
a eukaryotic promoter
25 a eukaryotic secretion signal; and
the lysostaphin gene from which two glycosylation sites in the lysostaphin gene from which two glycosylation sites in the lysostaphin gene were removed.

14. The gene of claim 11 wherein the gene encoding lysostaphin is modified as in SEQ ID NO: 3 which comprises:
- a eukaryotic start codon;
- the Kozak expression start site consensus sequence;
- 5 a eukaryotic promoter; and
- the lysostaphin gene from which two glycosylation sites in the lysostaphin gene from which two glycosylation sites in the lysostaphin gene were removed.
15. The gene of claim 11,12,13 or 14 wherein the gene encoding lysostaphin 10 comprises preprolysostaphin.
16. The gene of claim 11,12,13 or 14 wherein the gene encoding lysostaphin comprises prolysostaphin.
- 15 17. The gene of claim 11,12,13 or 14 wherein the gene encoding lysostaphin comprises mature lysostaphin.
18. A method for treating staphylococcal infection in a mammalian system, the method comprising expressing in the cells of the system, a modified gene encoding 20 lysostaphin.
19. The method of claim 18 wherein expressing the gene involves expressing a copy of the gene which is integrated into the cellular genome.
- 25 20. The method of claim 18 wherein the gene encoding lysostaphin is modified as compared to SEQ ID NO: 3 so that at least one mammalian regulatory sequence is operatively linked to the lysostaphin coding region and at least one glycosylation site is removed.


21. The method of claim 18 wherein the gene encoding lysostaphin is modified as in SEQ ID NO: 3 so that at least one mammalian regulatory sequence is operatively linked to the lysostaphin coding region and both glycosylation sites are removed.
22. The method of claim 18 herein the gene encoding lysostaphin is modified as in
- 5 SEQ ID NO: 3 which comprises:
- a eukaryotic start codon;
 - the Kozak expression start site consensus sequence;
 - a eukaryotic promoter
 - a eukaryotic secretion signal; and
- 10 the lysostaphin gene from which two glycosylation sites in the lysostaphin gene from which two glycosylation sites in the lysostaphin gene were removed.
23. The method of claim 21 wherein the gene encoding lysostaphin is modified as in SEQ ID NO: 3 which comprises:
- a eukaryotic start codon;
 - the Kozak expression start site consensus sequence;
 - a eukaryotic promoter; and
- 15 the lysostaphin gene from which two glycosylation sites in the lysostaphin gene from which two glycosylation sites in the lysostaphin gene were removed.
24. The method of claim 18,22, or 23 wherein the gene encoding lysostaphin
- 20 comprises preprolysostaphin.
25. The method of claim 18,22, or 23 wherein the gene encoding lysostaphin comprises prolysostaphin.
26. The method of claim 18,22, or 23 wherein the gene encoding lysostaphin comprises mature lysostaphin.

25

Abstract

The present invention relates to an improved approach for the treatment of microbial infections in mammals. Specifically, the invention provides methods and reagents for expressing in mammalian cells proteins that have anti-microbial activity. The invention provides both genes which have been modified to allow expression and preferably secretion of active protein in desired mammalian cells or tissues, and methods of introducing such modified genes into desired mammalian cells and/or tissues. Most specifically, genes encode anti-staphylococcal proteins are delivered to mammalian cells and/or tissues by methods of gene delivery, including gene therapy and the production of transgenic animals, for the treatment of mastitis in ruminant animals.

FIG. 1



2/29

FIG.2

TCCACCACATGG (Kozak site)

Pre-peptide Pro-peptide Mature lysostaphin

pCMLEM (Williamson et al. 1994)

pCMV-LYS GCCACCATGG (Kozak site) tga
 Mature lysostaphin

The diagram illustrates the genetic construct pCMV-hGH-Lys- Δ Gly1- Δ Gly2. It features a hGH signal peptide followed by the mature lysostaphin protein. The mature protein contains two Asn-Lys-Ser sequences, each preceded by an *atg* start codon and followed by a *tga* stop codon. Arrows above the sequence indicate the cleavage points for the removal of the signal peptide and the glycosylation sites.

3 / 29

FIG.3




FIG. 4

Plasmid	GH	Lys	GH	Lys	GH	Lys
Reaction buffers	-	-	-	+	+	+
N-Glycosidase-F	-	-	-	-	+	-





FIG. 5



6/29




FIG.7A




FIG.7B




FIG.7C



FIG.7D




FIG.7E





FIG.7F



8/29

FIG.8



9/29


FIG.9

1

2


3

4



10/29

FIG. 10



Lysostaphin
(ng/ml)

Dilutions of
Transgenic Milk

Dilutions of
Control Milk

FIG. 11-1

A.
ORIGIN

1 ccggaaacctt tgaatgttta gttttgaaaa ttccaaaaaa aacccctactt tcattaatatt
61 gattcatatt attttaacac aatcagttag aatttcaaaa atcttaaagt caatttttgaa
121 gtgtgttgtt atatttcattc aaaaatcaatc aatattttt tactttcttc atcgtttaaaa
181 atgttaatat ttataaaat atgcattct cataaatgtta ataaataattt aggaggattt
241 aaggttgaag aaaacaaaaa acaaatttta tacgagacctt ttagctattg gacttgatgtac
301 atttgcccta gcatctattg ttatgggg gattcaaaat gaaacacatg ctcttgaaaa
361 aatgttatq gatgttcaa aaaaaggtagc tgaaatgttagq acttcaaaag ccccagtaga
421 aaatacagct ggagttagaga ct tcaaaagc tcaggtagaa aatacagctg aagttagagac
481 tcaaaatgcttccatcaggact tcaaaaggctc cagttagaaaa
541 tacagctgaa gtagagactt caaaaggctcc ggttagaaaaat acagctgaaag tagagacttc
601 aaaaaggccca gtagaaaaata cagctgaagt agagacttca aaaaaggccctgg ttcaaaatag
661 aacagcttta agogctgcaa cacatgaaaca ttccggcacaa tggtgtgaata attacaaaaa
721 aggatatggt tacggtcctt atccattagg tataaatggc ggtatgcact acggaggatgaa

To Fig. 11-2

FROM FIG. 11-1

FIG. 11-2

781 tttttatg aatatggaa caccaggtaaa agcttattca agcggaaaa tagttgaagc
 841 tggttgggtt attacggg gggtaatca aataggcttt attgtaaaatg atggatgtca
 901 tagacaatgg tatatgtcatc taatgttc aaatgtttttt atgtcaaaagc
 961 tggtcaata atcggttgtt ctggaaagcac tggttattct acaggccac attacactt
 1021 ccaaaatgtt gttaattcat tttcattttc aactqcccaa gatccatgc ctttcttaaa
 1081 gagcgcggaa tatggaaaa cagggtggatc agtaactcca acgcccggata caggttggaa
 1141 aaaaaaaa tatggccac tatataatc aggttcacgt agcttcac ctaatacaga
 1201 tataataaca agaacggactg gtccatttag aagcatgccc cagtcaagg tcttaaagg
 1261 aggtcaaca attcattatg atgaatgtat gaaacaaagc ggtcatgttt gggtaggtta
 1321 tacaggtaac agtgcccaac gtatttactt gcctgtaaga acatggata aatctactaa
 1381 tacttttgtt gttctttggg gaactataaa gttagcgccgc tttttataaa ctttatatgt
 1441 aattagogca aataaaattttttttttt ccttaatgtt aagctt

To Fig. 11-3

FROM FIG.11-2

FIG.11-3

B.
BASE COUNT
ORIGIN

1 gctgcacac atgaaacattc agcacatgg ttagataatt accaaaaagg atatggttac
 61 ggtccatttc cattaggat aatggcggt atgcactacg gagttgattt tttagat
 121 attggacac cagtaaaagc tattcaagc gaaaaatag ttggactgg ttggatgtat
 181 tacggagg gtaatcaaatt ggctttattt gaaaatgtat gatgtgcata gcaatggtat
 241 atgcatactaa gtaataataa tgttaaagta ggagatatg tcaaggctgg tcaaataatc
 301 ggttgtctg gaogcacgtt tattctaca gcaccacatt tacacttcca aagaatggtt
 361 attcatttt caaatcaac tgccccat ccaatgccct tcttaaagg cgaggat
 421 ggaaaggcag gtggtagat aactccaaacg cggaaatacg gtggaaac acacaaatat
 481 ggcacactat ataaatcaga gtcagcttagc ttccacccat atacagat ataaacaaaga
 541 acgacttggtc catttagaaat catgcccacg tcaggatct taaaaggcagg tcaaacaatt
 601 cattatgtatg aagtgtatgaa acaagacgggt catgtttggg tagtttac aggttaacogt
 661 ggccaaacgtt tttacttggcc tggtaagaaaca tggaaataat ctactaatac tttaggttt
 721 ctttggggaa ctataaagtga

FIG. 12

"MKKTKNNYYTRPLAIGLSTFALASIIVYGGIQNETHASEKSNMDV
SKKVAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAE
VETSKAPVENTAEVETSKAPVENTAEVETSKALVQNRATLA
THEHSAQWLNNYYKKG
YGYGPYPLGINGGMHYGVDFFFMNI GTPVKAISSGKIV
EA GWSNYGGGNQIGLIE NDGV
HRQWYMHLSKYNVKVGDYVKAGQIIGWSGSTGYSTA
PHLHFQRMVNSFSNSTAQDPMP
FLKSAGYGKAGGTVPPTPNTGWKTNKYGTLYKSE
SASFTPNTDIITRTTGPFRSMPQS
GVLKAGQTIHYDEVMKQDGHVVWVGYT
GNSGQRIVLPVRTWNKSTNTLGVLWG
TIK"

FIG. 13

ORIGIN

1 gcccaaac atgaaacattc agcacaatgg ttgaataatt acaaaaagg atatggttac
 61 ggcccttatac cattaggat aaatggcggt atgcactacg gagttgatt ttttatgaaat
 121 attggaaacac cagtaaaagc tatttcaagg gaaaaaatag ttggaaatcg ttggaggtaat
 181 tacgggggg gtaatcaaat aggctttatt gaaaatgtg gagttgcatac acatggat
 241 atgcataa gtaataataa tgtaaagita ggagattatg tcaaaatcg tcaaataatc
 301 ggttggctcg gaagcacatg ttattctaca gcaccacatt tacacttcca oagaatggtt
 361 aactcattt cacagtcaac tgccccaggat ccaatgcctt tcttaaagg cgaggat
 421 gaaaaaggcag gtggtagt aactccaaacg ccgaatacag gttggaaac aaaaaatat
 481 ggccacat ataaatcaga gtcaggctac ttccacacca atacagatataaaacaaagg
 541 acgactggtc catttagaag catgccgca gtcaggatct taaaaggcagg tcaaacaat
 601 cattatgtg aagtgtatgaa acaaagacggt catgtttggg tagttatc aggttaacatg
 661 ggccaaacgtt tttacttggc tggcagaatgt ctactaatac tctgggtgtt
 721 ctgtggggaa ctataaaggta

FIG. 14-1

A.
ORIGIN

1 tgggtcgatccatttcg ttcatgtcg ccacgcac ggcgcgtt tgacgcgcga
 61 tcgcgcaccc tggtggat ggcgttcg caagcgatg tacggctcg
 121 atttggatgt gcgtcgacg acagggtcgcc gcccggc aggtccggc gcccggta
 181 taccggatgc gatcgccgg tccggatgt acgaaacggtc gtgcgtca gtcgcgtcq
 241 ccgtcgccg ctggcgatcc ggcttcg ggcgcgg gtcaccact cttcaaacgt
 301 ctttctcgaa aggacatataa gaaaggat tccaaaggcg gactgggtt ggcgtggtg
 361 tgccgtcgccg cgacgtcgcc ggcaacgca ggcgcagg ccacggcta gcggcgagg
 421 tctggtgtat tctacgacg gatgttcgac ttcgacatcg atggcatct ggccaaggcat
 481 qcggccgcattc tgccaaaggca ctggaaagg atctcgact gggccggcta caggggatc
 541 agccggatgt ttgtatcgcc tgatggaca gcaaggcg cggtcacgca aaggccgcga
 601 cggatcgatcc gttcgccaaatcgatcc gggccggctt cggccgcg acccggagg
 661 tcggctggc gctggcgatcc tcgttgtacg acggcgatcc cgacgcgcca aggggccgg
 721 gagcttggcc cggccaaatc cgctgcaggc gctgttcgatcgatcc gttccggcg acaacgagcc
 781 ggccggccgg ctggcgccg acggcgatgtt ccggcgatcc taaggccggcc tggccggatcgatcc

To Fig. 14-2

FROM FIG. 14-1

FIG. 14-2

FIG. 14-3

B.

"MKKISKAGLGLALVCALATIGNAARRATAQRRGSGVFYDEMFD

F D I DAHLAKHAPHLHKHSEE I SHWAGYSG I SRSVDRADGAERA VTPSARRIVRS
ASWRAPTA SARRPARSRWRCASRCTS A I PTRQGAGDAGPRQSAAGAVRAFRRQRAG
GRAARRRVPA GLRPPVQRTA PGQGGFFGPLRQGRPGR AAVSPNGLLQFPFPRGASWHVG
GAHTNTGSGNYPMSSLDMSRGCGWGSNQNQGNWVSASAAGSFKRHSSCFAE I VHTGG
WSTTYYHLMN I QYNTGANVSMNT A I ANPANTQAQALCNGGQSTGPHEHWSLKQNGSFYH
LN GTYLSGYR ITATGSSYDTNC SRFYLT KNGQNYCYGY YYVNP GPN"

FIG. 15-1

A.
ORIGIN

1 gaaaaattcca aaaaaaacc tactttctta atatgtttc atattttt cacacatca
 61 gtttagaaatt caaaaatctt aaaggtaatt tttaggttg tttgttat tcatcaaggc
 121 caatcaatat tattttactt tcttcatcgtaaaaaatgt aatattata aaaaatatgtc
 181 attctcataa atgtataat aaatttaggg gtatgttgt tgaagaaaaac aaaaaacaat
 241 tatatacga caccctttagc tatggatctg agtacatttg cttagatc tatttgttat
 301 ggaggattc acaaataaac acatgtttctt gaaaaatgt aatggatgt ttcaaaaaaa
 361 gtatgtgg tagatgttc aaaaaaccctt gtagaaaaata cagttggatg agggatctca
 421 aagctccgg tagaaatatac agtggatgtt gggacttca aagctccgtt aaaaaataca
 481 octggatgtt agacttcaaa agtccatgtt gaaaaatatac agtggatgtt tcggatgt
 541 ccaggtagaa atacatgtt aaaaaatgtt gggacttca aagctccgtt aaaaaataca
 601 gaaatgtt caatggatgtt aaaaaatgtt gggacttca aagctccgtt aaaaaataca
 661 ccaggtagaa atacatgtt aaaaaatgtt gggacttca aagctccgtt aaaaaataca
 721 gtagagactt caatggatgtt aaaaaatgtt gggacttca aagctccgtt aaaaaataca
 781 gtagaaata cagctggatgtt aaaaaatgtt gggacttca aagctccgtt aaaaaataca
 841 gagacttcaaa aagccccaggatgtt aaaaaatgtt gggacttca aagctccgtt aaaaaataca

To Fig. 15-2

FIG. 15-2

FROM Fig. 15-1

901 caaaataga a cagctttaag agctgcacaca catgaaacctt cagcacatg gtgtaaata
 961 tacaaaaaag gatattggtta cggtccttat ccatoggta taatggcg tatccactac
 1021 ggaggtgtatt ttttatgaa tattggaaaca ccagtaaaaaag ctatttcaag cggaaaaata
 1081 gttgaagctg gtggatgaa ttacggagga ggtaatcaa taggtttat tgaaatgtat
 1141 ggagtgcata gacaatggta tatgcatactaa agtaatata atgttaaagt oggagattat
 1201 gtcacaaataat gtcacaaataat cggttggctc ggaaggactg gttatctac ogcaccacat
 1261 ttacacttcc aaggatgtt taatttattt tcaaat tcaa ctgcccaga tccaaatgcct
 1321 ttctttaaga gcgcaggata tggaaaaagca ggtggtagq taactcaac gcccata
 1381 ggttggaaaa caaacaaaaa tggcacacta tataatcag agtcagctag cttcacacct
 1441 aatacagata taataacaag aacgactggt ccatattaaat gaaatgtaa acataaagt gaggcgccctt ttataaact
 1501 ttadaagcag gtcacaaataat tcattatgtt gaaatgtaa acataaagt gaggcgccctt ttataaact
 1561 gtaggtata caggtaacag tggccaaacgt atttacttgc ctgtaaac atggaaataa
 1621 tctactata cttaggtgt tctttagggta actataaagt gaggcgccctt ttataaact
 1681 tatatgataa ttagagcaaa taaaacttt ttcttcatttt taggttgaa gcttttcgta
 1741 atcatgtcat agcgtttccct gtgtggattt gttttttttt ccaattccac acacatacg
 1801 agccggaaaca taaatgtcta agcct

FIG. 15-3

B

"MKKTKNNYYTTPLAIGLSTFALASIYGGIQNETHASEKSNMDV

SKKVAEVETSKPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAE
VETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAE
PVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAE
EVETSKALVQNRTALRAATHEHSAQWLNNYKKGYGYGPYPPLGINGGIHYGVDFFMNIG
TPVKAISSGKIVEAGWSNYGGGNQIGLENDGVHIRQWYMHLSKYNNVKVGDYVKAGQII
GWSGSTGYSTAPHLHFQRMVNSFSNSTAQDPMPFLKSAGYGKAGCTVTPTPNTGWKTN
KYGTLYKSESESASFTPNTDIITRTTGFRSMPQSGVLKAGQTIHYDEVMKQDGHHWWVGY
TGNSCQRIYLPVRTWNKSTNTLGVLWGTIK"

ORIGIN

FIG. 16-1

1	gatattcattt caaaggacaga tattctaaag aaoagatata ttttaaaaaa tgtaggttgaa
61	aaaattaaag aaattcacga ttttgactat atatttatgg atgtaccacc tactatatac
121	tctgattca ctaataatgc tgtttacgca agtgattaca tttaatgg atttc当地
181	caacoaatctg cttatgaaag tagtc ttca ttgttttaatt tttaaggaa tc当地
241	gaatcaaggatt tatcatttga atggttggc gctgtccag tattatcaa aaaaatggaa
301	cgtgtagata aacagatatt agatatgtct oaattcaggcat ttctgaaagc actctttag
361	aaccgatat atcaaaagaga aagaataaaaaa aaatttgcgg ctgtatggat aaaaatggaa
421	gatatgcattg aaaaaaaagt tatatatatg tttaacaaag tctacgaaag attatgtat
481	agaggtagat taattgaaagg tgaggatgat ttatggcagg atttttagat aacatgata
541	catcttaggt aaaaatatacg gaaaattata accgggtatc taaaaggatcg actatgogg
601	tggacactga tataaaaaa agatthaatc aatggcggt agataaagat acatctataa
661	aggctatagt tgatggatgt ttagggaaat tttggaaaaa aaaaatgtat tagtatttta
721	tataggctt atactatla ggactgtga taatcactag tcctattt gataaaaaa
781	agcgcaattt tctctataat tagaaatgtatc ctaccacaa taattaaaggaa aataatgcgc
841	cattgtctaa tattatataca atcacccttg gaattaaaga taaaatatac actttttag
901	ataaggttga agaaatgtata aaggaaaaa ttctttattt tactttggaa aatatacata
961	ttctcccagg cgatgttaac ttgcggaca cggaaatatacg aacttttctta taatcaaaaa
1021	tggttttaaa aaatcatgtc ttacgatacc taaggatcg yagaagccag cttatttaat

22/29

To Fig. 16-2

FIG. 16-2

FROM FIG. 16-1

1081 attggaaaaa cagcgtttcc actgtaaaaa gtgcgtcgagt tatttcactg ctgaacacc
1141 tgtcgttttag tggaaattgtc atatttcctca aaacacacgta tttagctgtgc tgaatagaatc
1201 gatggacata cggtcgccaa aatctgttgc tgaatctgt catgtcagta attccacagt
1261 tactggaaa attaaataag ctgccttc aatagctcaa acaccgttta aatatttacc
1321 ggaacacttg atgatggatg agttccaaag cgttaaaaat gttgtcggtt aatatggatgtt
1381 tatttatgtca gatggatgtaa cacacccgtat tatttgtatt gtgcctgtacc gcgggttatt
1441 tgctttgtaaa aatttttctt accgttatcc tctttctgtaa tctttctgtaa gaaaaatgtg
1501 gtctattgtat atgtatggac ctttatggc tttgtatcggaa gatggatgtt
1561 aatttcataa gttcatttcc atattgttca gtcattaaat aaaaacccgt
1621 agtaaccgtt atgaatgtt tcggatccaa aactgccttg attctttaa aacttcata
1681 ttactggaaa attctttaa aactgccttta aatatttacc cggatccaa
1741 aaacttcata aacactgtta aacacgttca aatggatgtt tagaaatttt
1801 ggatacaatgtaa acttgaccaa cggttcaactt gaggggatgg atactaaaaat
1861 cagggaaatc ttttttttttta tagaaatttttggatgtt ggtgtatttac
1921 acaaaatcttt ttcgcgcgtaa tccaaaaaaa gagatcaagg aactttatgc
1981 ctgcgtttta gctcacccgtt cttattttgac agagagccaa taaaatttaac ggaggaggaa

To Fig. 16-3

23/29

24/29

FIG. 16-3

FROM FIG. 16-2

2041 ggatttcgaac caacgcgaac acatcacatgc tccttaataa taaaataataa ttaatccccct
2101 taatccagac ttgggtatcc ctccacaaggc atttttaat gctaataaa catabataac
2161 aacaaatgtaa aatatgtatt tataaggaaa aggatataa aattttctg agttatataa
2221 ggttgttcc ataaatcatcc taaaatgtaa gtcgaaaaggc ttcaacttta ggaatgagaa
2281 aaaaattttta tttgcctcaa ttatcatata agttataaa aagcgcgcgc actttatagt
2341 tccccaaaga acaccctaaag tatttagaa ttattccat gttcttacag gcaaggtaaat
2401 acgttgcca ctgttacctg tataacc tac ccaaaacatga ccgtcttgtt tcatcaatcc
2461 atcataatga attgtttgac ctgctttaa gactccgtac tgccggatgc ttctaaatgg
2521 accagtcggtt ctgtttatata tatctgtattt aggtgtgaag cttagctgact ctgatttata
2581 tagtgtgccat ttttcaacc ttgttttg tgatatttggc gtttggatgtt ctgtaccacc
2641 tgctttcca tatccgtcgc tctttaagaa aggcat tggat ctttggcag ttgaattttga
2701 aaaaatgtttt accattttt gggaaatgtaa atgttgtgtt gtagataaac cagtgcgttcc
2761 agaccaacgg atttttgac cagctttgac ataatctccat acttttaacat tatatttact
2821 tagatgcata taccattgtc tatgcactcc atcattttca ataagaccta tttgatttacc
2881 tcctcgtaa ttactccaaac cagcttcac tattttccg cttgaaatag cttttactgg
2941 tggttccaaaaa aatcaacactcc gtagtgtgcata ccggccatata taccctaaatgg

To Fig. 16-4

FIG. 16-4

FROM FIG. 16-3

3001 ataggaccg taaccatc ctttttgtta attattcaac catttgtctg aatgttcatg
3061 ttttgccagct cttaaaggct ttcttttgg aaccagggtt ttttgaggctt ctacttcagg
3121 tgattttctt actggggctt ttgaagtctc tacttcagct gtattttcta ccggaggcttt
3181 tgaaggctctt acttcaggctg tatttttctac tggagctttt ggagtcctca cttcaggctgt
3241 attttctact gggcttttg aagtctctac ttcaagctgtaa ttttttccgg gagcttttgc
3301 agtctctact tcaggctgtat tttctactgg agcttttgaa gtcctactt cagctgtatt
3361 ttctacttgg gcttttgagg tctctacttc agctgtattt tctaccggag ctttttggagg
3421 ctctacttca gctgtatttt ctacggagg ttttgaaagt tcactttcag ctgtattttc
3481 tacccggact ttttgaaagtctc tctacttcagg tgtatttct acttggaggctt ttgaagtc
3541 tacttcaactt gtttttctca ctggaggctt tgaagtcctc ttttctactt ggggcttttgc
3601 tggaggctcta cttcaggctgt attttctactt ggggcttttgc agtctctac
3661 ttcaagctact ttttttggaa catccatatt acttttttca gaagcatgtg tttcattttg
3721 aatcccctcca taacaatag atgcctaaaggc aaatgtactc agtccaaatag ctaaaggct
3781 cgtataatoo ttgttttttg ttttctcaa ctttaatacc tccataatttta ttattacatt
3841 tatgagaata gcatatttt ataaatatttta cattttttaa cgtatggaa agtacaaatoo
3901 tattgtattga ttttqatgaa atatcacaaaa acactcaaac attgacttta agattttggaa

To Fig. 16-5

FIG. 16-5

3961 aattcttaact gat ttgttta aataataatg aatcaaatatt aagaaggtag gtttttttt
4021 gggat ttca aaactaaaca ttcaaggattt cggaaatttt gtgttttcaa aaatgtccta
4081 ttacacaaat tctgcatttc attttgataata tagaaataacat cttcgaaata atgtgcattt
4141 agttggcgta aaaaatggaa caggtaaaggat attagctgt tgtttactga ctgaggccacg
4201 ttgtttaaag ttcttttaaat atttctatac acatcgccgtt ccaggcatga actttaaaga
4261 ccatgggtta gtcagattttttttatggaaa cttAACGCC tatctaaaaa agccaaactg
4321 cttatatgtt ttaactgacc cttaccgtttt aaaaaatttattt cggatgttg acggggaaat
4381 ccttgaatct tatgataaacg aacattttat gaacgtgtatg aattttat tag gttaccgtca
4441 tcaagggtt actacaggttt attctcaaac aagtcaagatc aatgtgttgtt cgttcttaaa
4501 ccttagaaaa aagatggaa aacaattttt aaaaatgtt aaaaatggat gattatcca cacggcgtaa
4561 tattaaagg accctatggaa tgccaggtaa agtcccgcat tttatcaatata atggaaacaga
4621 tcgattttt aattttat aatgtgttta aatggctga aaaaaacat ggttcaaat tcagagaaca
4681 aaggatttt gaaaggactgc aaaaaacata cggctgtataat aatgtgtttaa aatgtggctta
4741 catcgattta gaaaggatatt tagagacaca aaatgcggaa gtcgcgtgagg taataacaga
4801 tattggaaat attcaaggcg cat taaaaga aaaaatcaat tcttaaggaaa aaaaaataa
4861 atatgcgcaa taccaaaaacg aat tagcaggc acaaggaaacgaa aaaaattactg aacacgaaaaa

FROM Fig. 16-4

26/29

To Fig. 16-6

27/29

FIG. 16-6

FROM FIG. 16-5

4921 attgatagaa acagatggac ctgtat taga cttagctgca gcttactata tctatacccc
4981 tcatggagg ttactacctat ccagggtttc aaaccttaa tacaatgcct atatgggtgc
5041 gtacagactc caatggaaa tgattcaatt tgcggaaat aaaggatatt atcgcataaa
5101 ttttacggt attacaggag atttcagtga agatgtgaa gatttcggtg ttcaaggatatt
5161 caaaggaggc tttaatgccc atgttgaaaa atatgtcgcc gacttcatt aaccgattaa
5221 acctttat tataaattc atcaattatt aaatgatcaa ctgaaaaattt ttttagtcttt
5281 gttaaatcaa tatgacaccc caaaatgggt gttttacatt cttaaact aaggatctat
5341 atctcgacat cagcgagggt aaacggttcta gttttacatt aagcacccatc tccatcgaa
5401 atttttgtta acggaggatata tattgatatt ctgtaaat acaaggatatt atacttttga
5461 gaaggtaaga cgactatatt attataccat ctgtaaat catgtcggtt gtttcaaggat
5521 taacagacc ttgttagctga tgctggctat ggtagtaaaa gatctgaaaggatcgccg
5581 aaaaatata gctaaccact aatttatcat gtcagttttc actcaacttg cttagcatgt
5641 gctaatttcg tggcatggcg aaaatccgta tatgacgggt tctttttata
5701 tagacgtaa atacattcaa tacccttttaa agtattcttt gccgtatttga
5761 ccttgccttt cttactttaa tatgacgggt gcttgcctca ataaaggttat tccgatattt
5821 ctaggtacaa tgacgtcat gtttaaaggttt atgacttttag ccatggctac

To Fig. 16-7

FIG. 16-7

FROM FIG. 16-6

FIG. 17

"MKKTKNNYYTRPLAIGLSTFALASIIVYGGIQNETHASEKSNMDV
SKKVAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVET
NTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVET
SKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVETSKAPVENTAEVET
NTAEVETSKAPVENTAEVETSKALVQNRONTALRAATHEHSQAQWLNNYKKGYGYGPYP
LGINGGMHYGVDFFFMNIGTPVKAISSGKIVEAGWSNYGGNQIGLIENDGVHRQWYMH
LSKYNVKVGDYVKAGQIIGWSGSTAPHLHFQRMVNSFSNSTAQDPMPFLKSAGYG
KACGTVTPTPNTGWKTNKYGTLYKSESASFTPINTDIITRTTGPFRSMPQSGLVKAGQTIH
YDEVMKQDGHVVWGYTGNSGQRILPVRTWNKSTNTLGVLWGTIK"

DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TREATMENT OF STAPHYLOCOCCUS INFECTIONS

the specification of which (I authorize Choate, Hall & Stewart to check one of the following three choices, and fill in the blanks, if applicable):

 is attached hereto

X was filed on June 21, 1999 as Application Serial No. 09/337,079 and amended on _____ (if applicable).

_____ was filed as PCT international application No. _____, on _____ and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledged the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s): Priority Claimed

(Number)	(Country)	(Day/Month/Year/Filed)	Yes	No
----------	-----------	------------------------	-----	----

(Number)	(Country)	(Day/Month/Year/Filed)	Yes	No
----------	-----------	------------------------	-----	----

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.) (filing date) (status-patented, pending, abandoned)

(Application Serial No.) (filing date) (status-patented, pending, abandoned)

PCT Applications designating the United States:

(PCT Appl. No.) (U.S.S.N.) (status-patented, pending, abandoned)


I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national filing date of this application.

Provisional Application(s):

<u>60/090,175</u>	<u>June 22, 1998</u>	<u>Pending</u>
Application Number	Filing Date	Status

Application Number	Filing Date	Status
--------------------	-------------	--------

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United State Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full name of first inventor A. John Bramley
Inventor's signature 
Residence RR3, Box 1571, Hinesburg, VT 05461
Citizenship USA
Post Office Address _____

Full name of second inventor Karen I. Plaut
Inventor's signature _____ Date: _____
Residence RR1, 2222 Cambridge Road, Westford, VT
Citizenship USA
Post Office Address _____

Full name of third inventor David Kerr
Inventor's signature _____ Date: _____
Residence 2410 Dorset Street Extension, Charlotte, VT 05445
Citizenship USA
Post Office Address _____

Exchange.3019284.1

*Paula M. Delach
Notary Public*

DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TREATMENT OF STAPHYLOCOCCUS INFECTIONS

the specification of which (I authorize Choate, Hall & Stewart to check one of the following, three choices, and fill in the blanks, if applicable):

_____ is attached hereto

X was filed on June 21, 1999 as Application Serial No. 09/337,079 and amended on _____ (if applicable).

_____ was filed as PCT international application No. _____, on _____ and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledged the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s): Priority Claimed

(Number)	(Country)	(Day/Month/Year/Filed)	Yes	No
----------	-----------	------------------------	-----	----

(Number)	(Country)	(Day/Month/Year/Filed)	Yes	No
----------	-----------	------------------------	-----	----

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.) (filing date) (status-patented, pending, abandoned)

(Application Serial No.) (filing date) (status-patented, pending, abandoned)

PCT Applications designating the United States:

(PCT Appl. No.) (U.S.S.N.) (status-patented, pending, abandoned)

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national filing date of this application.

Provisional Application(s):

<u>60/090,175</u>	<u>June 22, 1998</u>	<u>Pending</u>
Application Number	Filing Date	Status

Application Number	Filing Date	Status
--------------------	-------------	--------

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United State Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full name of first inventor John A. Bramley

Inventor's signature _____ Date: _____

Residence RR3, Box 1571, Hinesburg, VT 05461

Citizenship USA

Post Office Address _____

Full name of second inventor Karen I. Plaut

Inventor's signature _____ Date: _____

Residence RR1, 2222 Cambridge Road, Westford, VT

Citizenship USA

Post Office Address _____

Full name of third inventor David Kerr

Inventor's signature David Kerr Date: Sept 2, 1999

Residence 2410 Dorset Street Extension, Charlotte, VT 05445

Citizenship USA CANADA

Post Office Address SAME AS RESIDENCE

DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TREATMENT OF STAPHYLOCOCCUS INFECTIONS

the specification of which (I authorize Choate, Hall & Stewart to check one of the following, three choices, and fill in the blanks, if applicable):

_____ is attached hereto

X was filed on June 21, 1999 as Application Serial No. 09/337,079 and amended on _____ (if applicable).

_____ was filed as PCT international application No. _____, on _____ and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledged the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s): Priority Claimed

(Number)	(Country)	(Day/Month/Year/Filed)	Yes	No
----------	-----------	------------------------	-----	----

(Number)	(Country)	(Day/Month/Year/Filed)	Yes	No
----------	-----------	------------------------	-----	----

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.) (filing date) (status-patented, pending, abandoned)

(Application Serial No.) (filing date) (status-patented, pending, abandoned)

PCT Applications designating the United States:

(PCT Appl. No.) (U.S.S.N.) (status-patented, pending, abandoned)

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national filing date of this application.

Provisional Application(s):

<u>60/090,175</u>	<u>June 22, 1998</u>	<u>Pending</u>
Application Number	Filing Date	Status

Application Number	Filing Date	Status
--------------------	-------------	--------

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United State Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full name of first inventor A. John Bramley

Inventor's signature _____ Date: _____

Residence RR3, Box 1571, Hinesburg, VT 05461

Citizenship USA

Post Office Address _____

Full name of second inventor Karen I. Plaut

Inventor's signature Karen Plaut Date: 11/8/99

Residence 210 Wooded View Drive, Los Gatos, CA 95032-5738

Citizenship USA

Post Office Address _____

Full name of third inventor David Kerr

Inventor's signature _____ Date: _____

Residence 2410 Dorset Street Extension, Charlotte, VT 05445

Citizenship USA

Post Office Address _____

U.S. GOVERNMENT PRINTING OFFICE: 1999 500-1000

ATTORNEY'S DOCKET NO.: 2001796-0005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bramley, et al.
Serial Number: 09/337,079
Filed: June 21, 1999
For: TREATMENT OF STAPHYLOCOCCUS INFECTIONS

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

APPOINTMENT OF ATTORNEY

The undersigned hereby appoints Brenda Herschbach Jarrell, Registration No. 39,223; Sam Pasternack, Registration No. 29,576; David J. Powsner, Registration No. 31,868; Elizabeth Nugent, Registration No. 43,839 and Kevin M. Tormey, Registration No. 41,351 as its attorneys and agents for prosecution of matters relating to the above-identified patent application and to conduct all business in the United States Patent and Trademark Office.

All correspondence should be sent to Brenda Herschbach Jarrell, Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, Massachusetts 02109.

Respectfully submitted,



Name: / Regina H. White, Director
Title: / Office of Sponsored Programs
On behalf of University of Vermont

Dated: SEP 27 1999, 1999

ATTORNEY DOCKET NUMBER: 2001796-0006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bramley, et al.

Serial No.:

Filed: October 27, 2000

For: TREATMENT OF STAPHYLOCOCCUS INFECTIONS

Assistant Commissioner For Patents
Washington, Dc 20231

Sir:


AMENDMENT INTRODUCING SEQUENCE LISTING

In the Specification

Beginning on a new page, immediately before the claims, please insert the attached Sequence Listing; please renumber subsequent pages accordingly.

Please charge any fees that may be associated with this matter, or credit any overpayments, to our Deposit Account No. 03-1721.

Respectfully submitted,


Brenda Herschbach Jarrell, Ph.D.
Reg. No.: 39,223

CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, Massachusetts 02109
Tel: (617) 248-5000
Fax: (617) 248-4000
Dated: October 27, 2000
3184704_1.DOC

SEQUENCE LISTING

<110> Bramley, John A.
Plaut, Karen I.
Kerr, David

<120> TREATMENT OF STAPHYLOCOCCUS INFECTIONS

<130> Mastitis

<140> 00/000,000

<141> 2000-10-27

<160> 10

<170> PatentIn Ver. 2.1

<210> 1

<211> 1486

<212> DNA

<213> Staphylococcus simulans

<400> 1

ccggaactct tgaatgttta gtttgaaaaa ttccaaaaaaaaaa aaacaccttctttaatattt 60
gattcatatt attttaaacac aatcagtttag aatttcaaaa atcttaaagt caattttga 120
gtgtgttgtt atatttcatc aaaatcaatc aatatttattt tactttcttc atcgtaaaaa 180
aatgttaatat ttataaaaaat atgctattct cataaatgttataataaaattt aggaggtatt 240
aagggttgaag aaaacaaaaaa acaatttatta tacgagacct ttagctattt gactgagttac 300
atttgcctta gcatctattt gttatggagg gattcaaaat gaaacacatg cttctgaaaa 360
aagtaatatg gatgtttcaa aaaaagttagc tgaagtagag acttcaaaag ccccaagttaga 420
aaatacagct gaagtagaga ctccaaaagc tccagtagaa aatacagctg aagtagagac 480
ttcaaaaagct ccagtagaaa atacagctg agtagagact tcaaaaagctc cagtagaaaa 540
tacagctgaa gtagagactt caaaagctcc ggttagaaaaat acagctgaaag tagagacttc 600
aaaagccccca gtagaaaaata cagctgaagt agagacttca aaagccctgg ttcaaaaatag 660
aacagcttta agagctgcaa cacatgaaca ttcagcacaa tggttgaata attacaaaaa 720
aggatatggc tacggccctt atccatttagg tataatggc ggtatgcact acggagttga 780
ttttttatg aatattggaa caccagtaaa agctatttca agcggaaaaaa tagttgaagc 840
tggttggagt aattacggag gaggtatca aataggtctt attgaaaaatg atggagtgca 900
tagacaatgg tatatgcac taagttaaaata gttaggagatt gttaggagatt atgtcaaagc 960
tggtaaaaata atcgggttggc ctggaaagcac tggttattct acagcaccac atttacactt 1020
ccaaagaatg gttaaatcat tttcaatttca aactgccccaa gatccaatgc ctttcttaaa 1080
gagcgcagga tatggaaaaag caggtggtagt agtaactcca acgcccata caggttggaa 1140
aacaacaaaa tatggcacac tatataaaatc agagtcaatc agcttcacac ctaatacaga 1200
tataataaca agaacgactg gtccatattt aagcatgccg cagtcaggag tcttaaaaagc 1260
aggtaaaca attcattatg atgaagtgtt gaaacaagac ggtcaatgttt gggtaggtt 1320
tacaggttaac agtggccaac gtattttactt gcctgtttaaga acatggaaata aatctactaa 1380
tacttttaggt gttctttggg gaactataaa gtgagcgcgc tttttataaaa ctttatatgtt 1440
aatttagagca aataaaaaattt ttttctcatt cctaaagttt aagttt 1486

<210> 2
<211> 388
<212> PRT
<213> Staphylococcus simulans

<400> 2
Met Lys Lys Thr Lys Asn Asn Tyr Tyr Thr Arg Pro Leu Ala Ile Gly
1 5 10 15

Leu Ser Thr Phe Ala Leu Ala Ser Ile Val Tyr Gly Gly Ile Gln Asn
20 25 30

Glu Thr His Ala Ser Glu Lys Ser Asn Met Asp Val Ser Lys Lys Val
35 40 45

Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val
50 55 60

Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser
65 70 75 80

Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Pro
85 90 95

Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn
100 105 110

Thr Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu
115 120 125

Val Glu Thr Ser Lys Ala Leu Val Gln Asn Arg Thr Ala Leu Arg Ala
130 135 140

Ala Thr His Glu His Ser Gln Trp Leu Asn Asn Tyr Lys Lys Gly Tyr
145 150 155 160

Gly Tyr Gly Pro Tyr Pro Leu Gly Ile Asn Gly Gly Met His Tyr Gly
165 170 175

Val Asp Glu Phe Met Asn Ile Gly Thr Pro Val Lys Ala Ile Ser Ser
180 185 190

Gly Lys Ile Val Glu Ala Gly Trp Ser Asn Tyr Gly Gly Asn Gln
195 200 205

Ile Gly Leu Ile Glu Asn Asp Gly Val His Arg Gln Glu Tyr Met His

210

215

220

Leu Ser Lys Tyr Asn Val Lys Val Gly Asp Tyr Val Lys Ala Gly Gln
225 230 235 240

Ile Ile Gly Trp Ser Gly Ser Thr Gly Tyr Ser Thr Ala Pro His Leu
245 250 255

His Phe Gln Arg Met Val Asn Ser Phe Ser Asn Ser Thr Ala Gln Asp
260 265 270

Pro Met Pro Phe Leu Lys Ala Ser Gly Tyr Gly Lys Ala Gly Gly Thr
275 280 285

Val Thr Pro Thr Pro Asn Thr Gly Trp Lys Thr Asn Lys Tyr Gly Thr
290 295 300

Leu Tyr Lys Ser Glu Ser Ala Ser Phe Thr Pro Asn Thr Asp Ile Ile
305 310 315 320

Thr Arg Thr Thr Gly Pro Phe Arg Ser Met Pro Gln Ser Gly Val Leu
325 330 335

Lys Ala Gly Gln Thr Ile His Tyr Asp Glu Val Met Lys Gln Asp Gly
340 345 350

His Val Trp Val Gly Tyr Thr Gly Asn Ser Gly Gln Arg Ile Tyr Leu
355 360 365

Pro Val Arg Thr Trp Asn Lys Ser Thr Asn Thr Leu Gly Val Leu Trp
370 375 380

Gly Thr Ile Lys

385

<210> 3

<211> 741

<212> DNA

<213> Staphylococcus simulans

<400> 3

gccgcaacac atgaacattc agcacaatgg ttgaataatt acaaaaaagg atatggttac 60
ggcccttatac cattagttat aaatggcggt atgcactacg gagttgattt ttttatgaat 120
attggaacac cagtaaaagc tatttcaagc ggaaaaatag ttgaagctgg ttggagtaat 180
tacggaggag gtaatcaa at aggtcttatt gaaaatgtat gagtgcatag acaatggat 240
atgcatactaa gtaaatataa tgtaaagta ggagattatg tcaaagctgg tcaaataatc 300
ggttggtctg gaagcactgg ttattctaca gcaccacatt tacacttcca aagaatggtt 360

aactcatttt cacagtcaac tgcccaagat ccaatgcctt tcttaaagag cgaggat 420
ggaaaagcag gtggtagt aactccaacg ccgaatacag gttggaaaac aaacaatat 480
ggcacactat ataaatcaga gtcagctacg ttcacaccta atacagat aataacaaga 540
acgactggtc cattagaag catgccgcag tcaggagtct taaaagcagg tcaaacaatt 600
cattatgtg aagtgtgaa acaagacggt catgtttggg taggttatac aggtaacagt 660
ggccaacgta ttacttgcc tgtgagaaca tggcagaagt ctactaatac tctgggtgtt 720
ctgtgggaa ctataaagt a 741

<210> 4
<211> 1520
<212> DNA
<213> Staphylococcus simulans

<400> 4
tgtgtgcgtg ctcccattcg ttcatgctcg ccacgcgcac ggccgcgtt tgacgcga 60
tcgcgcaccg tgtgaaccgc attgaggaat ggccgttcgg caagcgcatg tacggcctcg 120
atttgaacgt gcgtcgacg acagcgtcgc gccgcggc agagtccggc gcccgcggta 180
tacggacagc gatcgccgc tccgcccgtat acgaacggc gtgcgcgtca gtgcacatgcg 240
ccgctcgccg ctggcgttcc ggcttcgcgg gcgcagcgcg gtccaccact cttcaaacgt 300
ctttctcggg agcagcatat gaagaagatt tccaaggcgg gactggggct ggctgtgg 360
tgccgcgtgg cgacgatcgg cgccaacgcgca gcgcgcaggc ccacggctca gcggcgagga 420
tctgggttat tctacgacga gatgttcgac ttgcacatcg atgcgcacatc gccaagcat 480
gcgcgcgtc tgcacaagca ctcggaaagag atctcgact gggccggcta cagcgggatc 540
agccgaagtg ttgatcgcc tcatggagca gcagagcgcg cggtcacgc aagcgcgcga 600
cgaatcgcc gttcggcaag ctggcgcgcg ccgacggctt cggcgccgcg acccgcgagg 660
tcgcgcgtgc gctgcgcgag tcgctgtacg agcgcgatcc cgaacgcgcga agggggccgt 720
gacgcgtggcc cgcccaatc cgctgcaggc gctgttcgag cggtccggcg acaacgagcc 780
ggccggccgcg ctgcgcggcg acggcgagtt ccagctggc tacggccgcg tggtaacgc 840
accgcgcgcg gccaaggcgg ctgcggaccg ctgcggcaag gcccggccgg acgtgcagcc 900
gtgcgcgtcc acggcctgct gcagttcccc ttcccgccgcg gcgcgcgtcg gcatgtcgcc 960
ggccgcgcaca ccaacaccgg ctgcggcaat taccgcgtgt cgtgcgtggc catgtcgcc 1020
ggccggccgcg gggcagcaa ccagaacggc aactgggtgt cgccctcgcc cgccggctcg 1080
ttcaagcgcc actcttcgtg ctgcggag atcgtgcaca ccggcggtcg gtcgacgcacc 1140
tactaccacc tcatgtacat ccagtacaac accggcgcc acgtgtcgat gaacaccgc 1200
atcgccaaacc cggccaaacac ccaggcgcgcg gcgcgtgc acggcgccca gtcgaccggc 1260
ccgcacgcgcg atggcgtttt gaaacggc aacggcggtcg accacccaa cggcacctac 1320
ctgcggcgtt atcgcatcac cgcgcaccggc acgcgtatg acaccaactg cagccgggttc 1380
tatctgacca agaacggcc aactactgc tacggctatt acgtcaaccc gggccgcgaa 1440
tgaggcgtcgc cgcgtcgtt gcccgcgtcc tcaagcgccc cacgcgcggg ggcggggcac 1500
cgccgggtc aggtcgaaatt 1520

<210> 5
<211> 480
<212> PRT
<213> Staphylococcus simulans

<400> 5

Met Lys Lys Thr Lys Asn Asn Tyr Tyr Thr Thr Pro Leu Ala Ile Gly
1 5 10 15

Leu Ser Thr Phe Ala Leu Ala Ser Ile Val Tyr Gly Gly Ile Gln Asn
20 25 30

Glu Thr His Ala Ser Glu Lys Ser Asn Met Asp Val Ser Lys Lys Val
35 40 45

Ala Glu Val Glu Thr Ser Lys Pro Pro Val Glu Asn Thr Ala Glu Val
50 55 60

Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser
65 70 75 80

Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Pro
85 90 95

Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn
100 105 110

Thr Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu
115 120 125

Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr
130 135 140

Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala
145 150 155 160

Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu
165 170 175

Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala
180 185 190

Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu
195 200 205

Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys
210 215 220

Ala Leu Val Gln Asn Arg Thr Ala Leu Arg Ala Ala Thr His Glu His
225 230 235 240

Ser Ala Gln Trp Leu Asn Asn Tyr Lys Tyr Gly Tyr Gly Tyr Gly Pro
245 250 255

Tyr Pro Leu Gly Ile Asn Gly Gly Ile His Tyr Gly Val Asp Phe Phe
260 265 270

Met Asn Ile Gly Thr Pro Val Lys Ala Ile Ser Ser Gly Lys Ile Val
275 280 285

Glu Ala Gly Trp Ser Asn Tyr Gly Gly Asn Gln Ile Gly Leu Ile
290 295 300

Glu Asn Asp Gly Val His Arg Gln Trp Tyr Met His Leu Ser Lys Tyr
305 310 315 320

Asn Val Lys Val Gly Asp Tyr Val Lys Ala Gly Gln Ile Ile Gly Trp
325 330 335

Ser Gly Ser Thr Gly Tyr Ser Thr Ala Pro His Leu His Phe Gln Arg
340 345 350

Met Val Asn Ser Phe Ser Asn Ser Thr Ala Gln Asp Pro Met Pro Phe
355 360 365

Leu Lys Ser Ala Gly Tyr Gly Lys Ala Gly Gly Thr Val Thr Pro Thr
370 375 380

Pro Asn Thr Gly Trp Lys Thr Asn Lys Tyr Gly Thr Leu Tyr Lys Ser
385 390 395 400

Glu Ser Ala Ser Phe Thr Pro Asn Thr Asp Ile Ile Thr Arg Thr Thr
405 410 415

Gly Pro Phe Arg Ser Met Pro Gln Ser Gly Val Leu Lys Ala Gly Gln
420 425 430

Thr Ile His Tyr Asp Glu Val Met Lys Gln Asp Gly His Val Trp Val
435 440 445

Gly Tyr Thr Gly Asn Ser Gly Gln Arg Ile Tyr Leu Pro Val Arg Thr
450 455 460

Trp Asn Lys Ser Thr Asn Thr Leu Gly Val Leu Trp Gly Thr Ile Lys
465 470 475 480

<211> 492

<212> PRT

<213> Achromobacter lyticus

<400> 6

Met Lys Lys Thr Lys Asn Asn Tyr Tyr Thr Arg Pro Leu Ala Ile Gly
1 5 10 15

Leu Ser Thr Phe Ala Leu Ala Ser Ile Val Tyr Gly Gly Ile Gln Asn
20 25 30

Glu Thr His Ala Ser Glu Lys Ser Asn Met Asp Val Ser Lys Lys Val
35 40 45

Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val
50 55 60

Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser
65 70 75 80

Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Pro
85 90 95

Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn
100 105 110

Thr Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu
115 120 125

Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr
130 135 140

Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala
145 150 155 160

Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu
165 170 175

Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala
180 185 190

Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu
195 200 205

Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys
210 215 220

Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Leu Val

225 230 235 240
Gln Arg Thr Ala Leu Arg Ala Ala Thr His Glu His Ser Ala Gln Trp
245 250 255
Leu Asn Asn Tyr Lys Lys Gly Tyr Gly Tyr Gly Pro Tyr Pro Leu Gly
260 265 270
Ile Asn Gly Gly Met His Tyr Gly Val Asp Phe Phe Met Asn Ile Gly
275 280 285
Thr Pro Val Lys Ala Ile Ser Ser Gly Lys Ile Val Glu Ala Gly Trp
290 295 300
Ser Asn Tyr Gly Gly Asn Gln Ile Gly Leu Ile Glu Asn Asp Gly
305 310 315 320
Val His Arg Gln Trp Tyr Met His Leu Ser Lys Tyr Asn Val Lys Val
325 330 335
Gly Asp Tyr Val Lys Ala Gly Gln Ile Ile Gly Trp Ser Gly Ser Thr
340 345 350
Gly Tyr Ser Thr Ala Pro His Leu His Phe Gln Arg Met Val Asn Ser
355 360 365
Phe Ser Asn Ser Thr Ala Gln Asp Pro Met Pro Phe Leu Lys Ser Ala
370 375 380
Gly Tyr Gly Lys Ala Gly Gly Thr Val Thr Pro Thr Pro Asn Thr Gly
385 390 395 400
Trp Lys Thr Asn Lys Tyr Gly Thr Leu Tyr Lys Ser Glu Ser Ala Ser
405 410 415
Phe Thr Pro Asn Thr Asp Ile Ile Thr Arg Thr Thr Gly Pro Phe Arg
420 425 430
Ser Met Pro Gln Ser Gly Val Leu Lys Ala Gly Gln Thr Ile His Tyr
435 440 445
Asp Glu Val Met Lys Gln Asp Gly His Val Trp Val Gly Tyr Thr Gly
450 455 460
Asn Ser Gly Gln Arg Ile Tyr Leu Pro Val Arg Thr Trp Asn Lys Ser
465 470 475 480
Thr Asn Thr Leu Gly Val Leu Trp Gly Thr Ile Lys

485

490

<210> 7
<211> 741
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: altered S.
simulans lysostaphin gene

<400> 7
gctgcaacac atgaacattc agcacaatgg ttgaataatt acaaaaaagg atatggttac 60
ggtccttata cattaggtat aaatggcggt atgcactacg gagttgattt ttttatgaat 120
attggAACAC cagtaaaAGC tatttcaAGC ggaaaaATAG ttGAAGCTGG ttggagtaat 180
taCGGAGGAG gtaatcaaAT aggtcttattt gaaaatgatg gagtgcatag acaatggtat 240
atgcatactaa gtAAATATAA tggtaaAGTA ggagattatg tcaaAGCTGG tcaaATAATC 300
ggTTGGTCTG gaAGCAGTGG ttatttctaca gcaccacatt tacacttcca aagaatggtt 360
aattcatttt caaattcaac tgcccaagat ccaatgcctt tcttaaAGAG cgCAGGATAT 420
ggAAAAGCAG gtggTACAGT aactccaaACG ccgaatacAG gttggAAAAC aaACAAATAT 480
ggcacactat atAAATCAGA gtcagcttagc ttcacaccta atacagataat aataacaaga 540
acgactggTC catTTAGAAG catGCCGcAG tcaggagtct taaaAGCAGG tcaaACAATT 600
cattatgatg aagtgatgaa acaAGACGGT catgtttggg taggttatac aggtAACAGT 660
ggccaacgta ttacttgcc tgtaagaaca tggaaataat ctactaatac tttaggtgtt 720
cttggggaa ctataaAGTG a 741

<210> 8
<211> 480
<212> PRT
<213> Staphylococcus simulans

<400> 8
Met Lys Lys Thr Lys Asn Asn Tyr Tyr Thr Thr Pro Leu Ala Ile Gly
1 5 10 15

Leu Ser Thr Phe Ala Leu Ala Ser Ile Val Tyr Gly Gly Ile Gln Asn
20 25 30

Glu Thr His Ala Ser Glu Lys Ser Asn Met Asp Val Ser Lys Lys Val
35 40 45

Ala Glu Val Glu Thr Ser Lys Pro Pro Val Glu Asn Thr Ala Glu Val
50 55 60

Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser
65 70 75 80

Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Pro
85 90 95

Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn
100 105 110

Thr Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu
115 120 125

Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr
130 135 140

Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala
145 150 155 160

Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu
165 170 175

Asn Thr Ala Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala
180 185 190

Glu Val Glu Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu
195 200 205

Thr Ser Lys Ala Pro Val Glu Asn Thr Ala Glu Val Glu Thr Ser Lys
210 215 220

Ala Leu Val Gln Asn Arg Thr Ala Leu Arg Ala Ala Thr His Glu His
225 230 235 240

Ser Ala Gln Trp Leu Asn Asn Tyr Lys Tyr Gly Tyr Gly Pro
245 250 255

Tyr Pro Leu Gly Ile Asn Gly Gly Ile His Tyr Gly Val Asp Phe Phe
260 265 270

Met Asn Ile Gly Thr Pro Val Lys Ala Ile Ser Ser Gly Lys Ile Val
275 280 285

Glu Ala Gly Trp Ser Asn Tyr Gly Gly Asn Gln Ile Gly Leu Ile
290 295 300

Glu Asn Asp Gly Val His Arg Gln Trp Tyr Met His Leu Ser Lys Tyr
305 310 315 320

Asn Val Lys Val Gly Asp Tyr Val Lys Ala Gly Gln Ile Ile Gly Trp
325 330 335

Ser Gly Ser Thr Gly Tyr Ser Thr Ala Pro His Leu His Phe Gln Arg
340 345 350

Met Val Asn Ser Phe Ser Asn Ser Thr Ala Gln Asp Pro Met Pro Phe
355 360 365

Leu Lys Ser Ala Gly Tyr Gly Lys Ala Gly Gly Thr Val Thr Pro Thr
370 375 380

Pro Asn Thr Gly Trp Lys Thr Asn Lys Tyr Gly Thr Leu Tyr Lys Ser
385 390 395 400

Glu Ser Ala Ser Phe Thr Pro Asn Thr Asp Ile Ile Thr Arg Thr Thr
405 410 415

Gly Pro Phe Arg Ser Met Pro Gln Ser Gly Val Leu Lys Ala Gly Gln
420 425 430

Thr Ile His Tyr Asp Glu Val Met Lys Gln Asp Gly His Val Trp Val
435 440 445

Gly Tyr Thr Gly Asn Ser Gly Gln Arg Ile Tyr Leu Pro Val Arg Thr
450 455 460

Trp Asn Lys Ser Thr Asn Thr Leu Gly Val Leu Trp Gly Thr Ile Lys
465 470 475 480

<210> 9
<211> 1825
<212> DNA
<213> Staphylococcus simulans

<400> 9

gaaaaattcca aaaaaaaaaacc tactttctta atattgattc atattatttt aacacaatca 60
gttagaattt caaaaatctt aaagtcaatt tttgagtggt tttgtatatt tcataaaagc 120
caatcaatat tatTTactt tcTTcatcgT taaaaaatgt aatattttata aaaatatgct 180
attctcataaa atgtataat aaattaggag gtattaaggt tgaagaaaaac aaaaaacaat 240
tattatacga cacCTTtagc tattggactg agtacatttgc ctttagcatc tattgtttat 300
ggaggggattc aaaatgaaac acatgcttct gaaaaaagta atatggatgt ttcaaaaaaa 360
gtagctgaag tagagacttc aaaaccccccgtt gtagaaaaata cagctgaagt agagacttca 420
aaagctccag tagaaaatac agctgaagta gagacttcaa aagctccagt agaaaataca 480
gctgaagtag agacttcaaa agctccagta gaaaatacag ctgaagtaga gacttcaaaa 540
gctccggtag aaaatacagc tgaagtagag acttcaaaaag ctccggtaga aaatacagct 600

gaagtagaga cttcaaaagc cccagtagaa aatacagctg aagtagagac ttcaaaagct 660
ccagtagaaa atacagctga agtagagact tcaaaagctc cggtagaaaa tacagctgaa 720
gtagagactt caaaagcccc agtagaaaaat acagctgaag tagagacttc aaaagctcca 780
gtagaaaata cagctgaagt agagacttca aaagctccgg tagaaaatac agctgaagta 840
gagacttcaa aagccccagt agaaaataca gctgaagtag agacttcaa agccctggtt 900
caaaatagaa cagcttaag agctgcaca catgaacatt cagcacaatg gttgaataat 960
tacaaaaaaag gatatggta cggtccttat ccattagta taaatggcg tatccactac 1020
ggagttgatt ttttatgaa tatttgaaca ccagtaaaag ctatttcaag cgaaaaata 1080
gttgaagctg gttggagtaa ttacggagga ggtaatcaa taggtcttat tgaaaaatgat 1140
ggagtgcata gacaatggta tatgcata agtaaatata atgttaaagt aggagattat 1200
gtcaaagctg gtcaaataat cggttggtct ggaagcactg gttattctac agcaccacat 1260
ttacacttcc aaagaatggt taattcattt tcaaattcaa ctgcccaga tccaatgcct 1320
ttcttaaaga gcgcaggata tgaaaaagca ggtggtacag taactccaac gcccaataca 1380
ggttggaaaa caaacaataa tggcacacta tataatcag agtcagctg cttcacacct 1440
aatacagata taataacaag aacgactggt ccatttagaa gcatgccgca gtcaggagtc 1500
ttaaaagcag gtcaaacaat tcattatgat gaagtgtatga aacaagacgg tcatgtttgg 1560
gtaggttata caggttaacag tgcccaacgt atttacttgc ctgtaagaac atggaataaa 1620
tctactaata cttagtgttgc ttcttgggaa actataaagt gagcgcgcct tttataaact 1680
tatatgataa ttagagcaaa taaaaatttt ttctcattcc taaagttgaa gctttcgta 1740
atcatgtcat agcgttcct gtgtgaaatt gcttagcctc acaattccac acaacatacg 1800
agccggaaca taaagtgcta agcct 1825

<210> 10
<211> 6457
<212> DNA
<213> Achromobacter lyticus

<400> 10
gatatcattt caaagacaga tattctaaag aaaagatata ttttaaaaaa tgggttgaa 60
aaaattaaag aaattcacga ttttgactat atatttattt atgtaccacc tactattaac 120
tctgatttca ctaataatgc ttttacgca agtGattaca ttttaatggt atttcaaaca 180
caacaatctg cttatgaaag tagtcttca tttgttaatt ttttaaggga tcgaaaaaaaa 240
gaatcagatt tatcatgttga attgggtggc gctgttccag tattaattaa aaaaagtgg 300
cgtgttagata aacagatatt agatatgtct aaatcagcat tttctgaagc actctttgag 360
aaccagatatt atcaaagaga aagaataaaaa aaatttgcgg ctgatggaaat aaaagataaa 420
gatatgcattt acaaaaaagt tatatatatg ttttacaatgg tctacgaaga attagttgat 480
agagtttagat taatttgcagg ttagtgcata ttatggcagg atttttagat aacatagata 540
catctgaggt aaaatatacg gaaaattata aaccggatc taaaagtacg actatgagag 600
tggacactga tataaaaaaa agattaaatc aaatggcggtt agataaagat acatctataa 660
aggctatagt tgatgaagtg ttaggagaat ttttggaaaaaa aaataagtat tagtatttt 720
tataggctct atactatttta ggactgggtga taatcactag tccttatttt gataaaaaaa 780
agcgcaatta tctctataat tagaagtatc ctaccaccaa taattaaggaa aataatgcgc 840
ctatgtctaa tattatatca atcacccttg gaattaaaga taaaatatc acttttgcag 900
ataagggtga agaaagtata aagggaaaaaa ttcttttattt tactttggaa aattaataca 960
ttctcccaag cgatgttaaac ttgcggaca cgaaaatacg aacttttcta taatcaaaaaa 1020
tggttttaaa aaatcatgtc ttacgatacc taaggtatcg gagaagccag cttatttaat 1080
attggaaaaaa cagcgttcc actgtaaaaa gtgctgcagt tatttactg ctgaaacacc 1140

tgtcgttgag tggaattgct atatttctca aaacacacga ttagctgtgc tgaataagtc 1200
gatagacata cgttcgcaaa aatctgtgc tgaatcttgcatgtcagta attccacagt 1260
tactcgaata attaataaaag ctgcttctca aatagctcaa acaccgttt aatatttacc 1320
ggaacacacttg atgatggatg agttcaaaaag cgttaaaaat gttgtcggtaaatgagttt 1380
tatttatgca gatgcagtaa cacaccgtat tattgatatt gtgcctgacc gcaggattt 1440
tgctttgaaa aattatttct accgttatcc tctttctgaa agaaaaatgttgaaagcagt 1500
gtctattgtatgtatgaaac ctatatggc tttgatcaga gaagttttc ctaatgcca 1560
aattctaata gttcattcc atattgtca gtctttaaat aaagccttga acatgactcg 1620
agtaaacagtt atgaatagtt tcagaacaac tgaaagacccatataca agtacaagcg 1680
ttactggaag attctttaa aactgccttg aaaaatataaaatcaatag cgttgcct 1740
aaacttcaaa cagctgttaa aacactaaga aagcacaata gaatgataag aaatactttt 1800
gaatacagta acttgacca cgttcaactt gaggaaataa atactaaaat aaagctgata 1860
cagagaatat ctttggtaa tagaaatttt ggtgatttac gcagtcgtat cattttatgt 1920
acaaatctt ttgcagctaa tcacaaaaaaaaa gagatcaagc aactttatgc tgcttaatct 1980
ctgcgtttt gtcaccagt ctatatttgc agagagccaa taaaattaac ggagggagaa 2040
ggattcgaac caacgcgaac acatacatgc tcctaattaa taaaatataa ttaatcccct 2100
taatccagac ttgggtatcc ctccacaagc attatttaat gctaataataa catatataac 2160
aacaaatgtc aatatgtatt tataaggaaa aggatattaa aattattctg agttatataa 2220
ggtagtattc ataatcatcc taaagttgaa gtcgaaaagc ttcaacttta ggaatgagaa 2280
aaaattttta tttgctctaa ttatcatata agtttataaa aagcgcgctc actttatagt 2340
tccccaaaga acacctaag tattatgttataa gttattccat gttcttacag gcaagtaaat 2400
acgttggcca ctgttacctg tataacctac ccaaacatga ccgtcttgc ttcatcacttc 2460
atcataatga attgttgac ctgctttaa gactcctgac tgccgcattgc ttctaaatgg 2520
tagtgtgcca cttgttattatctgttattt aggtgtgaag cttagctgact ctgatttata 2580
accagtcgtt tatttgggg tttccaacc tgtattcggc gttggagttt ctgttaccacc 2640
tgctttcca tttctgcgc tctttaagaa aggatttggc tcttgggcag ttgaatttga 2700
aaatgaatta accattctt ggaagtgtaa atgtgggtct gtagaataac cagtgcctcc 2760
agaccaaccg attatttgac cagcttgcataatctctt acctttaacat tatatttact 2820
tagatgcata taccattgtc tatgcactcc atcattttca ataagaccta tttgattacc 2880
tcctccgtaa ttactccaac cagcttcaac tattttccg ctgaaataatcttactgg 2940
tgttccaata ttcataaaaaa aatcaactcc gtagtgcata ccgcattta tacctaatgg 3000
ataaggaccg taaccatatac ttttttgta attattcaac cattgtgctg aatgttcatg 3060
tgtgcagct cttaaagctg ttctatttt aaccagggttttgaagttct ctacttcagc 3120
tgtatatttct actggggctt ttgaagtc ttttcagct gtatatttctt ccggagctt 3180
tgaagtc ttttcagctg ttttcttac tggagctttt gaagtc ttttcttca cttagctgt 3240
attttctact ggggctttt aagtcttctac ttcagctgtt ttttcttaccg gagctttga 3300
agtcttact tcagctgtat ttttctactgg agcttttgaatgtctactt cagctgtatt 3360
tttctactggg gcttttgaag ttttctacttc agctgtattt ttttcttaccg gagctttga 3420
taccggagct ttttcttcaac ttttcttca cttagctgtt ttttcttca cttagctgt 3480
acttcagctg ttttcttac tggagctttt gaagtc ttttcttca cttagctgtt attttctact 3540
ggagctttt aagtcttctac ttcagctgtt ttttcttactgg gggctttga agtcttact 3600
tcagctactt ttttgaacatccatatta ttttcttca cttagctgtt ttttcttca 3660
atccctccat aaacaataga tgcttaaggca aatgtactca gtccttcaatgc taaaggcttc 3720
gtataataat tgtttttgc ttttcttcaac cttaataatctt ccttaatttatttattt 3780
atgagaatag catatttttaa taaatattac attttttaac gatgaagaaa gtaaaataat 3840
attgattgtat ttttgcatttttgcataacactcaac ttttcttactgg gtttttttttgc 3900
attcttaactg attgtgtttaa aataatatga atcaatattttaa agaaaatgttgg 3960
gaattttcaaa aactaaacat tcaagagttc gaagaatttgc ttttcttcaaaa aatgtctcat 4020

tacacacaat ctgcttctca ttttgaatat agaaaataacc atcagaataaa tgtgcattta 4080
gttggcgtaa aaaatgaaac aggtgaagta ttagctgctt gtttactgac tgaggcacgt 4140
tgtttaaagt tctttaaata tttctataca catcgccgtc cagtcatgaa cttaaagac 4200
catgagttag tcagatttt ttatgaaaac ttaacgacct atctaaaaaa gcaaaaactgc 4260
ttatatgttt taactgaccc ttacctgtta gaaaatattc gaagttgtga cggagaaatc 4320
cttgaatctt atgataacga aactttatg aacgtgatga atttattagg ttaccgtcat 4380
caagggttta ctacaggta ttctcaaaca agtcagatca gatgggtgtc ggtcttaaac 4440
ctagaaaata aagatgaaaa acaattgtta aaagaaaatgg attatcaaacc acgccgtaat 4500
attaagaaaa cctatgaaat gcaggtgaaa gtccgcgatt tatcaattaa tgaaacagat 4560
cgatTTTTTA aattatTTAA aatggctgaa gaaaaacatg gcttcaaata agttatTTTG 4620
aaagaatgca gaaaacatac gctgataata gtatgttaaa gctggcttac atcgatttag 4680
aagaattatt agagacacaa aatgcgaaag tcgctgagtt aaatacagat attgaaaata 4740
ttcaagcggc attaaaagaa aaccctaatt ctaagaaaaaa caaaaataaa tatgcgcaat 4800
acccaaagca attagcagca caagaacgaa aaattactga aacgaaaaaa ttgatagaaa 4860
cagatggacc tgtatttagac tttagctgcag cttaactataat ctatacccct catgaagtt 4920
actacctatc cagtggttca aaccctaaat acaatgccta tatgggtgcg tacagactcc 4980
aatggaaaat gattcaattt gcgaaaaata aaggtattaa tcgctataat ttttacggta 5040
ttacaggaga tttcagtgaa gatgctgaag atttcgggtgt tcaaaaattc aaagaaggct 5100
ttaatGCCCA tggtaagaa tatgtcggcg acttcattaa accgattaaa cctttatTTT 5160
ataaaattca tcaattatta aatagataac tggaaaattat ttagtctttg ttaatcaaata 5220
atgacacccctc aaaatgggtg tgaagagaac tatattttca aaggcgttaa tctcgacatc 5280
agcgaaggta aacgttctag ttttacattc ttaactacta agatgtata atttggttaa 5340
cgaagattat atgcatatta agcacctact tccatcgaaa atatcgccgg aagataagac 5400
gactatatta ttataccatc tgtaaatata caagcatata tacttctgat aacagaacct 5460
tgtagctgat gctggctatg gtagtaaaag taaggTTTTG tttcaagta aaaaatatacg 5520
ctaaccacta atttatcatg tcagtgttca ctcaacttgc tagcatgatg ctaatttcgt 5580
ggcatggcga aaatccgtag atctgaagag atctgcgggtt ctTTTtatAGACCgtaaa 5640
tacattcaat acctttaaa gtattcttg ccgtattgat actttgatac ctgtctttc 5700
ttactttaat atgacgggtgg ctttgctcaa taaggttatt ccgatatttc gatgtacaat 5760
gacagtcatg ttttaagttta aaagctttaa tgacttttagc catggctacc ttcgttgaag 5820
gtgcctgatc tgtaattacc ttttgagggtt tacccaaattt tttatgaga cgTTTgataa 5880
acgcatatgc tgaatgatta tctcgTTGT tacgcaagca aatatctaatt gtatgggttc 5940
tgtaaaaatt aatactttag aaaaccacgc attatataatgta tcactgatata ttatatttt 6000
atttcatata aatacttgaa caaaaatttcc atatttaatt ttctttgttgc actaacaata 6060
tttattttata agtatttgct gtcattattc taatttatgg aggccgtttt ttatgaactt 6120
taaatatttg tatgagaaat ttcttgat gagtcttgc tggatttttag tgcatttttt 6180
tgtcttaagt ggtattctga ctcccttttggaaattccaa taggtattat tttaggctta 6240
tatttggatg gattactaaa aaaggatgct tcttgatatt aacttaattt ttaataactc 6300
cagctaatta ctgttaaagt tgtataatta tttaaattaag gaaacattac aagaaaagga 6360
aatgcataatt tgatTTTCTC ttcttgtaa tggttataaaaa attaagatgt tataaccctat 6420
ctttatTTAAT gctataaaacc gtcgtccttg tgatatc 6457